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The  biological  clock  relies  on  the  integration  of  both  photic  and  non-photic  information  in 
order  to  synchronize  and  entrain  to  the  environment.  In  this  thesis  I  examine  the 
interaction  between  light  and  NPY,  a  known  mediator  of  many  non-photic  stimuli. 
Previous  studies  have  shown  that  both  photic  and  non-photic  stimuli  interact  in  vivo  and  in 
vitro.  However  the  precise  neural  pathways  and  cellular  mechanisms  utilized  in  such  a 
complex  interaction  are  as  yet  unknown. 
In  my  first  set  of  experiments  I  have  shown  that  microinjections  of  NPY  directly  onto  the 
suprachiasmatic  nucleus  (SCN)  in  vivo,  block  the  phase  advancing  effects  of  light  and 
attenuate  phase  delays.  Furthermore,  I  found  that  a  specific  NPY  Y1/Y5  receptor  agonist 
was  able  to  inhibit  photic  phase  shifts  in  a  similar  manner  to  that  observed  with  NPY. 
In  the  following  series  of  studies  I  utilized  a  newly  developed  NPY  Y5  receptor  antagonist. 
It  was  found  that  injection  of  the  Y5  receptor  antagonist  during  light  exposure  prevented 
NPY  from  inhibiting  light  induced  phase  shifts  during  the  night.  Also,  the  administration 
of  a  specific  Y1  receptor  antagonist  had  no  effect  on  the  ability  of  NPY  to  influence  the 
resetting  effects  of  light  during  the  early  and  late  night. 
It  was  previously  shown  that  phase  shifts  to  NPY  were  mediated  via  GABAergic 
intemeurons.  However,  I  found  that  NPY  did  not  inhibit  photic  phase  shifts  via  a  similar 
GABA  dependent  mechanism,  as  the  presence  of  bicuculline,  a  GABAA  antagonist  did  not 
prevent  NPY  from  altering  phase  shifts  to  light  during  the  night. 
2 Finally,  to  determine  the  possible  site  of  interaction  between  NPY  and  light  a  time  course 
study  was  designed.  It  was  found  that  microinjections  of  NPY  up  to  60  minutes  post  light 
exposure  were  able  to  attenuate  photic  phase  advances.  This  was  also  the  case  when 
animals  were  presented  with  a  novel  running  wheel  60  minutes  after  an  advancing  light 
pulse. 
Overall  my  work  has  shown  that  NPY  interacts  with  light  during  the  early  and  late  night. 
Furthermore,  NPY  utilizes  the  Y5  receptor  subtype  and  a  neural  pathway  independent  of 
GABAA  activation.  Finally  the  present  data  indicates  that  the  possible  site  of  interaction 
between  NPY  and  light  lies  downstream  from  receptor  binding  sites  within  SCN  cells. 
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13 Preface 
This  thesis  consists  of  six  chapters,  a  general  introduction  followed  by  four  experimental 
chapters  and  a  final  discussion  chapter.  Three  of  these  experimental  chapters  have  been 
published  and  one  has  been  submitted  for  review.  Following  these  six  chapters  are  four 
appendices  containing  a  detailed  description  of  the  surgical  procedures  used  throughout  the 
studies,  a  dose  response  analysis  for  the  novel  NPY  Y5  receptor  antagonist  used  in  chapter 
3,  activity  onset  calculation  methods  and  cannula  placement  verification  techniques.  The 
chapters  reproduced  here  are  identical  to  those  published  with  a  few  exceptions.  For  all 
chapters  the  introductions  have  been  shortened  to  avoid  repetition.  The  acknowledgement 
and  reference  sections  have  been  omitted  and  collated  at  the  end  of  the  thesis.  The  figures 
have  been  numbered  consecutively  throughout  the  work. 
The  full  references  for  published,  or  submitted  for  review  papers  are  as  follows: 
Chapter  2-  Lall,  G.  S.  and  Biello,  S.  M.  (2003)  Attenuation  of  circadian  light  induced  phase 
advances  and  delays  by  neuropeptide  Y  and  neuropeptide  Y  Y1/Y5  receptor  agonist. 
Neurosci.  119:  611-618. 
Chapter  3-  Lall,  G.  S.  and  Biello,  S.  M.  (2003)  Neuropeptide  Y  inhibits  photic  phase  shifts 
via  the  Y5  receptor.  Submitted  for  review. 
Chapter  4-  Lall,  G.  S.  and  Biello,  S.  M.  (2003)  Neuropeptide  Y,  GABA  and  circadian 
phase  shifts  to  photic  stimuli.  Neurosci.  120:  915-921. 
14 Chapter  5-  Lall,  G.  S.  and  Biello,  S.  M.  (2002)  Attenuation  of  phase  shifts  to  light  by 
activity  or  neuropeptide  Y:  a  time  course  study.  Brain  Res.  957:  109-116. 
The  relative  contribution  of  authors  is  as  follows.  For  all  papers  included  in  this  thesis,  the 
original  ideas  for  experiments  were  generated  through  interactions  with  my  supervisor,  Dr. 
Stephany  M.  Biello.  These  experiments  were  designed  by  me,  but  were  critically 
evaluated  by  Dr.  Biello.  The  papers  were  written  by  me  but  received  editing  from  Dr. 
Biello. 
15 Abbreviations 
CT  Circadian  Time 
DD  Constant  Darkness 
GABA  y-amino  butyric  acid 
GHT  Geniculohypothalamic  Tract 
IGL  Intergeniculate  Leaflet 
LD  Light-Dark  Cycle 
LGN  Lateral  Geniculate  Leaflet 
NPY  Neuropeptide  Y 
NMDA  N-methyl-D-aspartate 
PRC  Phase  Response  Curve 
RHT  Retinohypothalamic  Tract 
SCN  Suprachiasmatic  Nucleus 
ZT  Zeitgeber  Time 
16 Chapter  1 
General  Introduction 
1.1  Circadian  Rhythms 
Throughout  evolution  humans  have  shown  the  ability  to  adapt  and  alter  their  physiological 
and  behavioral  patterns  in  accordance  with  environmental  and  social  changes.  Many 
physiological  and  behavioral  rhythms  exhibited  by  humans  follow  an  observable  circadian 
(close  to  24  hours)  pattern.  Sleeping,  energy  metabolism,  hormonal  secretions  are  just  a 
few  examples  of  factors  that  repeat  with  a  circadian  rhythm  of  expression.  These  circadian 
rhythms  have  been  primarily  governed  by  the  environmental  day-night  cycle.  However  we 
are  able  to  modify  these  rhythms  by  other  behavioral  influences  such  as  social  activities  or 
shift  work.  This  displays  the  ability  of  humans  to  integrate  both  environmental  and 
behavioral  information  to  generate  an  internal  physiological  rhythm  that  allows  us  to 
perform  at  maximum  potential  and  allows  maximal  flexibility  within  our  ever-changing 
life  styles.  Our  natural  internal  and  external  circadian  rhythms  not  only  allow  us  to  adapt 
to  environmental  changes  but  also  more  importantly  help  regulate  vital  biological 
processes  within  specific  organs,  ultimately  at  a  level  of  homeostatic  maintenance. 
1.2  The  Endogenous  Clock 
The  endogenous  rhythm  of  the  circadian  clock  exhibits  an  approximate  twenty-four  hour 
cycle  in  mammals.  Under  constant  conditions  of  darkness  many  species  exhibit 
behavioural  patterns,  which  cycle  with  a  circadian  rhythm.  The  observed  behavioural 
patterns  under  these  conditions  display  the  endogenous  rhythm  of  the  circadian  clock,  as 
there  is  no  influence  from  environmental  cues,  such  as  day  and  night  changes.  Animals 
under  these  conditions  are  said  to  be  `free  running'. 
17 Tau  (ti)  or  the  `free  running  rhythm'  is  a  measure  of  the  rate  of  change  of  the  measurable 
circadian  parameter  relative  to  time,  normally  cycling  with  a  period  of  approximately  24 
hours.  Changes  in  r  can  be  measured  by  recording  biological  events  that  exhibit  a 
circadian  pattern,  for  example  daily  activity.  An  actogram  can  be  used  as  a  graphical 
representation  of  an  animal's  daily  activity  over  a  number  of  days.  Wheel  running  activity 
is  widely  used  as  a  means  of  measuring  activity.  Figure  1  illustrates  a  schematic  actogram 
of  wheel  running  activity  of  an  animal  under  constant  conditions  plotted  on  a  24  hour 
scale. 
The  start  of  activity  each  day  provides  information  about  the  x  of  an  animal.  An 
inclination  to  the  left  indicates  ar  shorter  than  twenty-four  hours  i.  e.  onsets  of  activity  are 
earlier  each  day,  whereas  an  inclination  to  the  right  indicates  ax  longer  than  twenty-four 
hours  i.  e.  onsets  of  activity  are  later  each  day. 
1.3  Entrainment. 
The  endogenous  nature  of  the  circadian  clock  may  be  observed  in  the  free  running 
situation,  but  out  of  the  experimental  laboratory,  environmental  cues  govern  the  rhythm  of 
the  clock. 
The  environmental  day-night  cycle  can  be  termed  a  zeitgeber  meaning  `time  giver'.  If  the 
zeitgeber  is  effective,  then  the  internal  clock  will  synchronise  to  it  and  so  be  entrained. 
The  process  of  entrainment  can  be  defined  as  the  synchronisation  of  the  biological  clock  to 
the  outside  world  by  adjusting  to  a  twenty-four  hour  day. 
18 An  entrained  animal  will  show  an  activity  onset  that  is  synchronised  with  the  external 
zeitgeber.  For  example  a  nocturnal  animal  entrained  to  a  light  dark  cycle  will  display 
activity  when  the  lights  go  off.  If  a  species  entrains  to  such  a  stimulus  then  its  activity 
pattern  will  remain  synchronised  with  the  given  zeitgeber  i.  e.  in  nocturnal  animals  activity 
will  start  at  lights  off  each  day.  Figure  2  shows  a  schematic  actogram  of  an  animal 
entrained  to  a  light  dark  cycle.  The  process  of  entrainment  involves  the  circadian 
pacemaker  resetting  itself  to  the  zeitgeber  each  day. 
1.4  The  circadian  time  scale 
In  circadian  biology  two  separate  time  scales  are  used  to  refer  to  entrained  species  and  to 
those  that  are  kept  under  constant  conditions.  Animals  that  are  entrained  to  a  zeitgeber  are 
said  to  follow  a  zeitgeber  time  (ZT)  scale,  with  ZT12  defined  as  the  time  of  activity  onset 
for  nocturnal  animals  and  ZTO  for  diurnal  species.  Circadian  time  (CT)  is  assigned  to 
animals  that  are  kept  under  constant  conditions  and  one  circadian  day  is  a  measure  of  the 
time  taken  for  the  internal  biological  clock  to  complete  one  cycle.  For  example,  for 
nocturnal  animals  CT12  is  defined  as  the  time  of  activity  onset  and  CTO  for  diurnal 
animals.  This  means  that  the  interval  from  CT12  to  CT24  still  refers  to  the  night,  in  both 
nocturnal  and  diurnal  species.  Most  significantly,  the  study  of  subjects  under  constant 
conditions  allows  the  observation  of  an  individuals  circadian  rhythm  governed  by  its 
internal  clock  as  oppose  to  the  external  environment. 
For  experimental  purposes  animals  are  either  entrained  to  a  light  dark  cycle  thereby  using  a 
ZT  time  scale,  or  left  to  free  run,  thereby  using  the  CT  time  denomination.  Under  the 
influence  of  a  zeitgeber  it  is  possible  to  observe  the  clock  under  the  control  of  external 
19 stimuli  so  allowing  the  study  of  the  circadian  system  as  it  functions  under  the 
environmental  day  night  cycle.  However  in  order  to  examine  the  endogenous  rhythm  of 
the  clock  it  is  necessary  to  remove  entraining  stimuli  such  as  the  environmental  light  dark 
cycle  therefore  utilising  the  CT  time  scale. 
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Figure  1.  A  schematic  actogram  of  an  animal  under  constant  conditions.  The  solid  black  bars  represent 
activity.  Measuring  the  rate  of  change  of  activity  onsets  over  a  number  of  days  allows  the  calculation  of  tau 
i.  e.  the  natural  period  of  the  circadian  clock. 
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Figure  2.  A  schematic  actogram  of  an  animal  entrained  to  a  24  hour  light  dark  cycle.  The  open  bars  at  the 
top  of  the  actogram  indicate  lights  on  and  the  dark  bars  indicated  lights  off.  This  actogram  depicts  the 
activity  pattern  of  a  nocturnal  animal;  hence  activity  starts  when  light  go  off.  This  behavioural  pattern  is 
repeated  each  day,  indicating  that  the  animals  has  synchronised  to  the  environmental  light  dark  cycle 
imposed  on  it. 
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1.5.1  Photic  regulation  of  the  clock 
The  environmental  light  dark  cycle  provides  perhaps  the  strongest  zeitgeber  for  the 
entrainment  of  the  circadian  pacemaker.  Over  time  light  has  played  a  key  role  in  the 
development  and  survival  of  many  species.  Food  availability  and  predator  avoidance  are 
just  two  aspects  of  survival  that  animals  associate  with  light  or  darkness  and  so  have 
altered  their  activity  patterns  in  order  to  maintain  a  high  survival  rate. 
Throughout  evolution  the  biological  clock  has  been  well  conserved.  The  effects  of  brief 
light  pulses  on  locomotor  activity  in  rodents  maintained  in  constant  conditions  have  been 
well  studied.  Pittendrigh  (1976)  originally  found  that  light  pulses  caused  consistent  shifts 
in  the  phase  of  the  activity  rhythm.  The  magnitude  and  direction  of  the  shift  depends  on 
the  time  (relative  to  the  animal's  clock)  at  which  the  pulses  of  light  are  presented.  These 
responses  to  light  are  remarkably  similar  across  species. 
In  mammals,  light  pulses  presented  during  the  "early  subjective  night"  (the  time  in  the 
animal's  clock  that  would  correspond  to  darkness  if  the  animal  were  entrained  to  a  light 
dark  cycle),  cause  phase  delays.  Light  pulses  presented  during  the  "late  subjective  night" 
cause  phase  advances,  and  pulses  presented  during  most  of  the  "subjective  day"  (the  time 
in  the  animal's  clock  that  would  correspond  to  light  if  the  animal  were  in  entrained  to  a 
light  dark  cycle)  results  in  no  phase  shifts  (Pittendrigh  and  Daan,  1976).  By  plotting  the 
magnitude  of  the  phase  shift  and  the  timing  of  the  light  pulses,  it  is  possible  to  construct  a 
graph,  which  shows  the  extent  of  the  phase  shifts  obtained  when  light  pulses  are  presented 
23 at  given  times  of  the  animals  circadian  clock.  Such  graphs  are  called  phase  response 
curves  (PRC).  Figure  3  illustrates  a  schematic  PRC  for  light  in  mammals. 
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Figure  3.  A  schematic  phase  response  curve  for  light.  Light  pulses  given  at  CT2  have  no  effect  on  the  clock, 
pulses  given  at  CT14  cause  phase  delays  and  pulses  given  at  CT18  result  in  phase  advances. 
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Non-photic  stimuli  include  temperature  variation,  social  interactions,  food  and  water 
availability  and  novel  wheel  exposure.  Phase  response  curves  observed  to  non-photic 
stimuli  show  phase  advances  during  the  subjective  day  and  very  little  effect  during  the 
subjective  night  (Mrosovsky  et  al.,  1989).  Animals  confined  to  novel  wheels  show 
consistent  phase  shift  in  a  manner  similar  to  the  non-photic  PRC  (Ralph  and  Mrosovsky, 
1992).  Figure  4  illustrates  a  typical  non-photic  phase  response  curve.  Novel  wheel 
exposure  is  thought  to  phase  shift  by  inducing  arousal.  For  example  hamsters  that  do  not 
run  in  the  novel  wheel  do  not  show  non-photic  phase  shifts  (Reebs  and  Mrosovsky,  1989). 
This  may  be  because  these  animals  are  not  aroused  by  the  stimulus. 
Entrainment  to  non-photic  stimuli  can  be  vital  for  the  survival  of  a  species.  Times  of  food 
availability,  predator  avoidance  and  social  interaction  are  just  a  few  examples  of  non- 
photic  stimuli  that  are  essential  for  the  success  of  a  species.  Throughout  evolution 
organisms  have  had  to  integrate  both  photic  and  non-photic  information  for  survival. 
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Figure  4.  A  schematic  non-photic  phase  response  curve.  Non-photic  stimuli  show  phase  advances  during  the 
subjective  day,  and  more  variable  phase  delays  during  the  subjective  night. 
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Circadian  Time  (h) 1.6.  Neuroanatomy 
1.6.1.  The  Circadian  Pacemaker. 
The  earliest  studies  of  the  location  of  the  internal  pacemaker  were  focused  on  the  neural 
mechanisms.  Lesion  studies  by  Ritcher  in  1967  concluded  that  only  destruction  of  the 
hypothalamus  disrupted  the  free  running  activity  cycles  in  rats  (Ritcher,  1967).  This  then 
led  to  further  work  attempting  the  localisation  of  the  pacemaker  within  the  hypothalamus. 
Microlesions  placed  within  the  hypothalamus  combined  with  behavioural  observations 
monitoring  free  running  activity  cycles  identifies  the  central  pacemaker  to  be  located 
within  the  anterior  hypothalamus,  specifically  in  an  area  known  as  the  suprachiasmatic 
nuclei  (SCN)  (Fig.  5)  (Moore  and  Eichler,  1972;  Stephan  and  Zucker,  1972). 
Lesions  of  the  SCN  disrupt  such  cycles  as  sleep-wake  patterns,  hormonal  secretions, 
activity  rhythms,  eating  and  drinking  patterns,  reproductive  and  temperature  cycles  and 
corticosterone  rhythms  (Moore  and  Eichler,  1972;  Stephan  and  Zucker,  1972;  Abe  et  al., 
1979).  Further  conclusive  evidence  using  transplantation  techniques  showed  that  the  SCN 
was  the  site  of  the  circadian  pacemaker.  Neural  grafts  of  SCN  tissue  were  transplanted 
into  hamsters  with  lesions  of  the  SCN  and  the  recipient  recovered  with  the  period  of  the 
donor  (Ralph  et  al.,  1990).  The  donor  animals  used  for  this  study  were  from  a  mutant 
strain  of  hamsters  with  a  very  short  tau. 
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Figure  5.  Illustration  of  a  coronal  section  of  a  hamster  brain.  The  location  of  the  SCN  is  indicated  just  above 
the  optic  chiasm  and  below  the  third  ventricle.  The  SCN  consists  of  two  bilaterally  paired  nuclei  (Morrin  et 
al,  Hamster  atlas  2000). 
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Three  major  afferent  pathways  have  been  found  to  convey  both  environmental  and 
behavioral  information  to  the  SCN.  Photic  signals  project  from  the  retina  via  the 
retinohypothalamic  tract  (RHT),  directly  to  the  SCN  (Moore  and  Lenn,  1972).  However,  a 
second  indirect  route  for  light  signals  to  be  transmitted  to  the  SCN  also  exists.  Terminals 
from  the  retina  also  synapse  onto  the  intergeniculate  leaflet  (IGL)  of  the  lateral  geniculate 
nucleus  within  the  thalamus  (Pickard  et  al.,  1987),  which  in  turn  projects  directly  onto  the 
SCN  via  the  geniculohypothalamic  tract  (GHT)  (Harrington,  1997).  Non-photic 
information  is  also  relayed  to  the  SCN  via  two  predominant  routes.  Firstly  via  the  GHT 
originating  from  the  IGL  (Harrington,  1997)  and  from  the  raphe  nuclei  (Azmitia  and  Segal, 
1978).  The  dorsal  raphe  innervates  the  IGL  while  the  median  raphe  synapses  directly  onto 
SCN  terminals.  Figure  6  illustrates  the  various  inputs  of  the  SCN. 
1.6.3.  Neurotransmitters  of  the  circadian  system 
Neurotransmitters  utilised  by  the  afferent  pathways  of  the  SCN  act  to  regulate  pacemaker 
activity  and  provide  information  about  the  environment,  such  as  length  of  daylight.  The 
RHT  is  primarily  responsible  for  mediating  photic  information  to  the  SCN.  The  principal 
neurotransmitter  of  this  pathway  is  thought  to  be  the  excitatory  amino-acid  glutamate, 
which  binds  to  glutamatergic  receptors  located  on  SCN  cells  (Ebling,  1996). 
Numerous  neurotransmitters  have  been  implicated  in  mediating  the  effects  of  non-photic 
stimuli  to  the  SCN.  The  IGL  utilizes  neuropeptide  Y  (NPY),  Gamma-amino-butyric  acid 
(GABA)  and  enkephalin  as  neurotransmitters,  whilst  the  raphe  nucleus  utilizes  serotonin  in 
30 conveying  non-photic  information  to  the  SCN  (Ajika  and  Ochi,  1978;  Decavel  and  Van 
den  Pol,  1990;  Moore  and  Speh,  1993;  Morin  and  Blanchard,  1995)(Fig.  6). 
Previous  neurochemical  studies  have  shown  that  a  number  of  neuropeptide  Y-immuno- 
reactive  (NPY-ir)  neurons  originate  from  within  the  IGL  in  many  species  including  rat, 
hamster  and  cat  (Card  and  Moore,  1988,1989;  Covenas  et  al.,  1990;  Morin  and  Blanchard, 
1995).  A  majority  of  NPY-ir  cells  also  contain  the  neurotransmitter  gamma-aminobutyric- 
acid  (Francoisbellan  et  al.,  1990).  Neuronal  fibres  originating  from  the  IGL  also  show 
immunoreactivity  for  serotonin,  enkephalin,  histamine  and  substance  P,  however  not  all  of 
these  afferents  innervate  the  SCN  (Agarwala  et  al.,  1992;  Morin,  1992).  At  present, 
predominate  innervation  from  the  IGL  to  the  SCN  appears  to  be  from  fibres  containing 
NPY,  GABA  and  enkephalins. 
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Figure  6.  Illustrates  the  major  afferent  pathways  that  synapse  onto  the  SCN.  These  inputs  and  their 
associated  neurotransmitters  are  thought  to  be  the  major  regulators  of  the  SCN. 
32 1.7.  NPY  and  non-photic  resetting  of  the  circadian  clock. 
1.7.1.  Mediation  of  non-photic  stimuli  by  NPY 
Non-photic  stimuli  have  been  studied  in  many  animal  models,  with  the  hamster  being 
among  the  most  observed  due  to  its  robust  circadian  pattern  of  activity.  In  nocturnal 
animals  non-photic  stimuli  reset  the  circadian  pacemaker  during  the  mid-  subjective  day, 
i.  e.  the  rest  phase  in  nocturnal  rodents  and  have  little  or  no  effect  during  the  subjective 
night,  the  active  phase  in  nocturnal  rodents 
Behavioral  arousal  is  amongst  the  most  powerful  of  these  non-photic  stimuli  in  the 
hamster.  One  method  of  invoking  such  arousal  is  by  placing  an  animal  into  a  novel 
environment,  such  as  confinement  to  a  novel  running  wheel.  Hamsters  confined  to  a  novel 
running  wheel  can  become  aroused  by  the  new  surroundings  and  this  elevated  level  of 
excitement  leads  to  excessive  running.  Those  animals  that  run  tend  to  phase  shift  to  the 
stimulus  if  presented  during  the  mid-subjective  day  (Reebs  and  Mrosovsky,  1989). 
The  involvement  of  NPY  in  the  non-photic  resetting  of  the  circadian  clock  was  shown 
using  the  novel  wheel  stimulus.  Lesions  of  the  IGL  abolish  the  phase  shifting  effects  of 
novelty-induced  wheel  running  (Janik  and  Mrosovsky,  1994).  Electrical  stimulation  of  the 
GHT  produces  a  PRC  that  resembles  that  of  a  non-photic  stimulus  (Rusak  et  al.,  1989). 
The  cannula  administration  of  NPY  onto  the  SCN  in  vivo  produces  PRC's  similar  to  those 
observed  with  the  novel  wheel  (Biello  and  Mrosovsky,  1996).  Furthermore,  the 
application  of  NPY  to  the  SCN,  in  vitro,  produces  shifts  in  cellular  firing  rhythms 
comparable  to  non-photic  stimuli  (Biello  et  al.,  1997b).  Finally,  antiserum  raised  against 
33 NPY  microinjected  onto  the  SCN  via  a  cranial  cannula  implant  in  vivo,  inhibited  the  phase 
shifts  to  novel  wheel  exposure  during  the  mid-subjective  day  (Biello,  1995). 
1.7.2.  The  modulation  of  photic  phase  shifts  by  non-photic  stimuli. 
Photic  and  non-photic  stimuli  have  been  shown  to  interact  with  each  other  when  presented 
simultaneously.  Discoveries  of  such  interactions  have  shown  the  versatility  of  the  circadian 
system  and  how  rapidly  it  can  respond  to  different  stimuli.  Novel  wheel  running  can 
attenuate  light  induced  phase  advances  when  administered  together  during  the  late 
subjective  night  (Ralph  and  Mrosovsky,  1992).  The  processes  by  which  such  attenuation 
can  occur  is  unclear. 
The  RHT  appears  to  be  the  sufficient  for  the  synchronization  of  the  circadian  pacemaker  to 
a  light-dark  cycle  (Rusak  and  Zucker,  1979).  However  some  alterations  in  the  pattern  of 
entrainment  are  seen  after  lesions  of  the  IGL  (Harrington  and  Rusak,  1986;  Pickard  et  al., 
1987;  Johnson  et  al.,  1989).  Furthermore,  the  IGL  and  the  SCN  are  innervated  by 
collaterals  from  the  same  set  of  retinal  neurons  (Pickard,  1985).  In  addition,  NPY 
containing  fibres  from  the  IGL  project  to  the  ventrolateral  portion  of  the  SCN,  which  is 
also  innervated  by  the  RHT  (Card  and  Moore,  1988).  Also,  it  was  shown  that  neurons 
activated  by  stimulation  of  the  RHT  are  more  likely  to  respond  to  the  application  of  NPY 
than  those  not  activated  (Shibata  and  Moore,  1988).  These  studies  indicate  that  the  IGL  is 
involved  in  the  modulation  of  photic  responses  to  light  within  the  circadian  system. 
Hamsters  with  complete  lesions  of  the  GHT  show  significant  decreases  in  phase  advance 
shifts  produced  by  light  pulses  (Harrington  and  Rusak,  1986).  However,  Harrington  and 
34 Rusak  (1986)  found  no  effect  of  GHT  lesions  on  phase  delays  to  light,  while  Pickard  et  al 
(1987)  reported  larger  phase  delays  with  light  in  GHT  lesioned  animals.  Furthermore 
animals  with  LGN  lesions  show  significant  retardation  in  the  re-entrainment  to  a  new  light- 
dark  cycle  (Harrington,  1997).  Hamsters  with  IGL  lesions  have  a  free  running  period  in 
constant  light  similar  to  that  in  constant  darkness  (Harrington  and  Rusak,  1988),  while 
intact  hamsters  show  lengthened  free  running  periods  in  constant  light. 
Microinjections  of  antiserum  raised  against  NPY,  via  indwelling  intracranial  cannula's 
aimed  directly  at  the  SCN  in  vivo,  results  in  the  potentiation  of  light  induced  phase 
advances  in  the  hamster  (Biello,  1995).  Furthermore  NPY  administration  prior  to  light 
exposure  during  the  early  night  attenuate  the  photic  phase  shift  at  this  time,  however  phase 
delays  to  light  are  unaffected  by  NPY  injections  (Weber  and  Rea,  1997). 
Taken  together  this  evidence  indicates  the  involvement  of  the  GHT  and  NPY  in  the 
modulation  of  photic  phase  shifts.  In  order  for  such  regulation  to  occur  both  photic  and 
non-photic  pathways  must  interact.  Currently,  the  precise  mechanism  and  site  of 
interaction  is  unknown. 
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Recent  cloning  and  pharmacological  studies  have  identified  six  major  NPY  receptors;  Y1, 
Y2,  Y3,  Y4,  Y5  and  Y6.  This  family  of  NPY  Y  receptors  has  been  pharmacologically 
defined  by  its  ability  to  bind  NPY,  neuropeptide  YY  (PYY),  pancreatic  polypeptide  (PP) 
and  synthetic  derivatives  of  these  compounds  (Wahlestedt  and  Reis,  1993;  Gehlert,  1994; 
Chen  and  van  den  Pol,  1996). 
Ligand  binding  studies  using  autoradiology  have  aided  in  the  characterization  of  these 
NPY  Y  receptors.  The  binding  profiles  and  rank  order  of  binding  potencies  are  as  follows: 
Y1  binds  NPY,  PYY,  [Leu31,  Pro34]NPY  and  COOH-terminal  fragments  of  NPY  (Herzog  et 
al.,  1992;  Larhammar  et  al.,  1992),  Y2  binds  NPY,  PYY  and  COOH-  terminal  fragments  of 
NPY;  Y3  binds  NPY  and  PYY  (Gerald  et  al.,  1995;  Rose  et  al.,  1995);  Y4  binds  PP,  NPY, 
PYY  (Bard  et  al.,  1995;  Lundell  et  al.,  1995;  Yan  et  al.,  1996)  and  the  Y5  binds  NPY, 
PYY,  [Leu31,  Pro34]NPY,  NPY2"36,  human  PP  and  COOH-  terminal  fragments  of  NPY 
(Gerald  et  al.,  1996),  while  the  Y6  receptor  binds  NPY,  PYY,  [Leu3t,  Pro34]NPY,  NPY2-36, 
NPY13"36  and  human  PP  (Weinberg  et  al.,  1996).  However,  the  Y6  gene  is  present  in  most 
species,  but  encodes  foe  a  non-functional  receptor  (Weinberg  et  al.,  1996). 
Anatomical  location  studies  (in  situ  hybridization  histochemnical  techniques)  show  that  the 
topographical  distribution  of  NPY  Y  receptor  expression  in  the  central  nervous  system  is 
sparse.  The  Y1  and  the  Y2  receptors  have  been  located  in  the  paraventricular  nucleus 
(PVN),  arcuate  nucleus  (Arc)  and  the  lateroanterior  hypothalamic  nucleus.  The  Y4 
receptor  was  only  identified  in  the  PVN.  The  Y5  receptor  was  localized  to  the  Arc. 
However  it  was  found  that  both  the  Y1  and  Y5  receptors  were  present  in  the  SCN  (Larsen 
36 and  Kristensen,  1998).  Within  the  SCN  the  topographical  distribution  and  expression  of 
the  Y1  and  Y5  receptors  is  predominantly  restricted  to  the  ventrolateral  portion  of  the 
SCN,  where  the  majority  of  NPY  immunoresponsive  nerve  fibres  are  also  found  (Card  and 
Moore,  1982;  Mikkelsen,  1990).  This  region  of  the  SCN  also  receives  afferent  nerve  fibres 
from  the  visual  system  both  via  direct  and  indirect  routes  generating  from  the  GHT  (Moore 
and  Lenn,  1972;  Swanson  et  at.,  1974;  Card  and  Moore,  1989;  Mikkelsen,  1990). 
Neuropeptide  Y  Y2  receptor  expression  was  observed  within  the  vicinity  of  the  SCN  but 
not  in  the  nucleus  itself  (Gustafson  et  al.,  1997).  These  studies  are  consistent  with  in  vivo 
behavioural  work  showing  the  presynaptic  role  of  the  Y2  receptor  in  the  mediation  of  NPY 
phase  shifts  (Huhman  et  al.,  1996)  and  with  the  post  synaptic  role  of  the  Y1/Y5  receptors 
in  the  inhibition  of  photic  resting  (Lall  and  Biello,  2003b).  At  present  little  is  known  about 
the  topography  of  the  Y3  receptor. 
Very  little  is known  regarding  the  associated  intracellular  signal  transduction  cascades  for 
the  NPY  Y  receptors.  At  present  it  is  know  that  all  NPY  Y  receptors  characterized  are  G- 
protein  coupled  (Balasubramaniam,  1997).  The  NPY  Y1  receptor  has  been  associated  with 
the  activation  of  phospholipase  C  via  a  G-protein  linked  mechanism  (Parker  et  al.,  1998). 
Also  the  NPY  Y5  receptor  was  found  to  cause  the  inhibition  of  cyclic  AMP  accumulation, 
suggesting  that  activation  of  this  receptor  influences  second  messenger  pathways  (Gerald 
et  al.,  1996). 
The  majority  of  the  pharmacological  characterization  of  all  NPY  Y  receptors  has  been 
conducted  using  specific  agonists.  Examples  of  NPY  agonists  would  include  NPY,  PP, 
37 PYY,  [Leu31,  Pro34]NPY  and  NPY2  36.  All  these  agonists  bind  to  various  NPY  Y  receptors 
with  varying  potencies.  Recently,  many  behavioural  studies  have  relied  on  the 
development  of  specific  NPY  Y  receptor  antagonists.  The  commercial  availability  of  NPY 
Y  receptor  antagonists  has  been  extremely  limited.  However,  private  laboratories  and 
independent  pharmaceutical  companies  have  developed  a  few  antagonists  for  some  of  the 
NPY  receptor  subtypes.  Currently  Boerhinger  pharmaceuticals  have  developed  two  Y1 
receptor  antagonist  (BIB03304  and  BIBP3226)  and  one  Y2  receptor  antagonist 
(BIIBE0246)  (Doods  et  al.,  1999;  Dumont  et  al.,  2000).  Also  a  novel  Y5  antagonist  has 
recently  been  developed  by  Johnson  and  Johnson  pharmaceuticals  (RWJ57926).  It  is 
likely  that  antagonists  for  the  various  other  NPY  Y  receptors  are  probably  under 
development. 
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1.9.1  The  molecular  loop 
The  first  `clock'  gene  to  be  discovered  was  identified  in  the  Drosophila  and  was  called  the 
Drosophila  Period  (Per)  gene  (Konopka  and  Benzer,  1971).  Analysis  of  the  kinetics  of 
this  gene's  expression  led  to  the  generation  of  a  simple  molecular  model  (Hardin  et  al., 
1990)  which  was  found  to  be  the  basis  of  all  the  genetic  models  used  to  study  circadian 
rhythms  in  the  majority  of  species.  This  model  consists  of  gene  transcription  and 
consequent  translation  steps  leading  to  the  formation  of  a  protein.  The  protein  produced 
then  directly  or  indirectly  inhibits  its  own  transcription  and  the  cycle  restarts  following 
protein  degradation.  This  process  can  take  place  with  an  approximate  24  hour  oscillation 
of  RNA  and  protein,  as  is  observed  for  many  clock  genes  and  their  protein  products.  This 
forms  the  basis  of  a  molecular  loop  that  has  a  simple  negative  feedback  system  with 
several  components,  each  of  which  depends  on  the  previous  component  in  the  loop;  for 
example,  the  rate  of  protein  synthesis  depends  on  RNA  levels  transcribed.  The  initial 
feedback  model  for  the  Drosophila  involved  just  one  gene  and  its  two  components,  RNA 
and  protein  (Hardin  et  al.,  1990).  Recent  advances  in  genetic  research  has  led  to  the 
identification  of  many  more  components,  however  they  all  form  part  of  the  same 
transcription-translation  feedback  loop,  functioning  as  activators,  inhibitors  or  kinases. 
The  discovery  and  development  of  the  mammalian  circadian  molecular  mechanism  came, 
initially,  from  the  study  of  mutants.  The  first  mutant  to  be  studied  was  the  tau  mutant 
hamster.  The  tau  mutant  hamster  possesses  a  clock  that  `runs'  a  lot  faster  than  that 
observed  in  the  wild  type  (Ralph  and  Menaker,  1988).  Large-scale  mutant  screening  in  the 
mouse  aided  the  discovery  of  the  CLOCK  (Clk)  gene,  which  has  now  been  cloned  and 
39 found  to  encode  for  transcription  factor  (Gekakis  et  al.,  1998).  Period  genes  were  later 
identified,  in  mammals,  using  available  gene  sequences  (Albrecht  et  al.,  1997)  and  various 
homolog  searches  (Tei  et  al.,  1997).  These  results  showed  that  many  species  shared  the 
same  clock  genes.  It  was  found  that  the  `core'  of  the  mammalian  molecular  loop  consisted 
of  three  Per  genes  (Perl,  Pert  and  Per3),  two  cryptochrome  (Cryl  and  Cry2)  genes,  a  Clk 
gene  and  a  gene  called  BMAL1  (Brain,  Muscle  And  Liver  protein)  (Reppert  and  Weaver, 
2001).  Cell  transfection  experiments  and  genetics  have  allowed  the  understanding  of  how 
these  genes  and  their  products  work.  Results  from  experiments  using  these  techniques 
have  showed  that  Per  and  Cry  expression  is  activated  by  a  Clk-BMAL1  dimer,  which 
binds  to  a  specific  promotor  sequence,  the  `E-box',  CACGTG,  while  Per  and  Cry  proteins 
dimerise  and  inhibit  their  own  transcription  by  influencing  Clk-BMAL1  activation 
(Gekakis  et  al.,  1998;  Hogenesch  et  al.,  1998).  In  order  for  the  dimerisation  of  the  Per 
protein  to  occur,  Per  must  first  be  phosphorylated.  Period  phosphorylation  is  mediated  by 
Casein  kinase  le  (Ckle)  (Reppert  and  Weaver,  2001).  Once  phosphorylated  Per  can  freely 
bind  to  Cry  to  form  stable  heterodimers.  Within  the  Per-Cry  dimer,  Cry  provides  the 
repressor  function  (Kume  et  al.,  1999),  while  the  role  of  Per  is  not  entirely  clear  in  the 
mechanism  of  the  negative  feedback  loop  (figure  7).  A  positive  effect  was  found  for  the 
Pert  protein  on  BMAL1  levels  (Shearman  et  al.,  2000). 
Within  this  autoregulatory  loop  it  has  been  found  that  the  three  Per  and  two  Cry  homologs 
can  mix  and  match  to  form  different  complexes  (Kume  et  al.,  1999).  Furthermore,  new 
components  have  recently  been  discovered  such  as  Rev-ErbBa,  which  functions  as  a 
nuclear  receptor  that  regulates  the  effects  of  BMAL1  (Preitner  et  al.,  2002).  The 
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SCN  cells. 
Under  constant  conditions  both  Per  and  Cry  display  an  endogenous  rhythm  (Reppert  and 
Weaver,  2001).  These  rhythms  have  been  localized  to  specific  regional  area  within  the 
SCN.  In  rats,  peak  expression  of  both  Perl  and  Pert  RNA  under  constant  conditions  is 
greatest  in  the  dorsomedial  SCN;  however  endogenous  rythmicity  of  Perl  and  Pert  is  also 
seen  in  the  ventral  SCN  of  the  rat,  particularly  at  the  rostal  level  (Dardente  et  al.,  2002).  In 
mice,  endogenously  rhythmic  Perl  and  Pert  is  also  topographically  organized  and  is 
present  in  rostal,  dorsomedial  and  ventromedial  portions  of  the  SCN,  but  is  absent  from  the 
central  and  ventrolateral  regions  of  the  mid  and  caudal  SCN  (LeSauter  et  al.,  2003). 
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Figure  7.  A  simplified  diagrammatic  representation  of  the  molecular  clock  in  a  mammalian  SCN  cell. 
CLOCK-BMAL1  (Clk-BMAL1)  induces  Period  gene  (Perl  and  Pert)  expression.  Cryptochrome  genes 
(CryI  and  Cry2)  are  also  expressed.  Within  the  SCN  cell  cytosol  Per  and  Cry  proteins  are  produced.  Per 
proteins  are  phosphorylated  (pPerl  and  pPer2)  by  Casein  Kinase  le  (Ckle).  pPerl  and  pPer2  form  dimers 
with  Cryl  and  Cry2,  which  then  negatively  feedback  into  the  nucleus  to  inhibit  Per  transcription. 
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Behavioural  shifts  in  circadian  rhythms  observed  with  brief  pulses  of  light  during  the 
subjective  night  occur  via  altering  gene  expression  within  the  cells  of  the  SCN.  The 
expression  of  Perl  and  Per2  can  be  induced  by  light  pulses  presented  during  the  night 
(Albrecht  et  al.,  1997;  Shigeyoshi  et  al.,  1997;  Yan  et  al.,  1999).  Levels  of  Perl  and  Pert 
RNA  rapidly  increase  after  15  to  30  minutes  of  light  exposure  (Shearman  et  al.,  1997; 
Shigeyoshi  et  al.,  1997;  Yan  et  al.,  1999).  It  has  been  shown  that  the  degree  of  induction 
of  Perl  expression  is  dependent  on  the  phase  of  the  clock.  Also  Perl  expression  is 
induced  at  time  points  when  light  phase  shifts  the  clock.  Furthermore,  the  degree  of  Per 
induction  is  directly  related  to  the  size  of  the  phase  shift  (van  Esseveldt  et  al.,  2000). 
Finally  in  vivo  photic  and  glutamate  induced  phase  shifts  can  be  blocked  by 
intracerebroventricular  application  of  Perl  RNA  antisense  oligonucliotides  (Akiyama  et 
al.,  1999),  further  indicating  the  critical  role  of  the  period  genes  in  the  response  to  photic 
stimuli. 
Photic  phase  shifts  have  been  shown  to  increase  Per  transcription  at  times  when  levels  of 
Per  transcription  are  low.  In  the  endogenous  rhythm  of  the  SCN  Per  transcription  is 
initiated  by  the  binding  of  the  Clk-BMAL1  dimer  to  the  promotor  site  of  the  Per  genes. 
However,  during  the  early  and  late  night  photic  pulses  initiate  Per  transcription  via  the 
phosphorylation  of  Ca2+/cyclic  AMP  response  element  binding  proteins  (CREB)  which 
lead  to  CRE-mediated  transcription  activation  (Ginty  et  al.,  1993;  Ding  et  al.,  1997; 
Obrietan  et  at.,  1999).  This  mechanism  in  the  induction  of  Per  transcription  allows  the 
rapid  increase  in  Per  protein  synthesis,  ultimately  leading  to  a  photic  resetting  response. 
43 During  the  early  night,  when  light  pulses  cause  phase  delays  in  behavioural  rhythms,  light- 
induced  Perl  is  expressed  within  the  ventrolateral  and  central  SCN  in  both  rats  and  mice 
(Shigeyoshi  et  al.,  1997;  Yan  and  Okamura,  2002).  However,  the  localization  of  Pert 
expression  is  not  clear.  Initially  it  was  shown  that  Pert  was  expressed  predominantly  in 
the  ventrolateral  and  central  SCN  following  light  pulses  during  the  early  night  (Yan  and 
Okamura,  2002),  but  also  in  this  study  Pert  expression  was  seen  in  the  dorsomedial  SCN. 
Therefore,  the  regional  specificity  of  Pert  expression  during  a  photic  pulse  is  not  absolute. 
These  molecular  studies  clearly  show  the  key  components  involved  in  the  molecular 
resetting  effects  of  photic  stimuli.  Future  studies  are  likely  to  identify  the  precise  role  of 
these  molecular  genes  in  the  mediation  of  phase  delays  and  advances  to  light. 
44 1.9.3  Non-photic  phase  shifts  at  the  molecular  level 
Currently  the  majority  of  molecular  research  looking  at  the  resetting  effects  of  various 
stimuli  has  been  focused  on  photic  stimuli  i.  e.  light  and  glutamate  induced  phase  shifts.  At 
present  there  is  minimal  data  available  for  the  influences  of  non-photic  stimuli  on  the 
molecular  mechanism  within  the  SCN. 
Non-photic  resetting  has  been  shown  to  influence  Period  expression.  Confinement  of 
hamsters  to  a  novel  running  wheel  during  the  day  results  in  non-photic  phase  shifts  of  the 
clock  (Mrosovsky,  1996).  Such  shifts  have  been  linked  to  the  down  regulation  of  Perl  and 
Pert  mRNA  levels  (Maywood  et  al.,  1999).  However,  little  is  known  about  other 
molecular  influences  of  non-photic  stimuli,  but  it  is  clear  that  the  period  genes  are  the 
targets  for  both  photic  and  non-photic  resetting  cues. 
45 The  Present  Study 
As  reviewed,  the  biological  clock  is  responsible  for  generating  and  regulating  a  circadian 
rhythm  and  is  located  in  the  SCN.  Information  regarding  the  environmental  light-dark 
cycle  is  conveyed  to  the  SCN  via  the  RHT,  which  consists  of  a  direct  connection  from  the 
retina  to  the  clock.  A  secondary  indirect  pathway  from  the  retina  to  the  SCN  via  the  IGL  is 
also  present.  This  pathway  is  likely  to  be  responsible  for  conveying  both  photic  and  non- 
photic  information  to  the  SCN. 
From  the  evidence  cited,  it  seems  that  NPY  projections  from  the  IGL  to  the  SCN  plays  a 
role  in  the  modulation  of  light  induced  resetting  of  the  circadian  clock.  This  thesis 
contains  a  series  of  experiments,  which  attempt  to  identify  the  mechanism  utilized  by  NPY 
in  its  interaction  with  light  during  the  early  and  late  subjective  night. 
My  hypothesis  is  that  NPY  modulates  the  phase  shifting  effects  of  light  during  the  early 
and  late  subjective  night. 
Chapter  2 
Microinjections  of  NPY  during  the  late  subjective  night  have  been  shown  to  inhibit  phase 
advances  to  light,  in  vivo  (Weber  and  Rea,  1997).  However,  in  the  same  study  phase 
delays  to  light  were  unaffected  by  NPY  administration.  These  results  differed  from  those 
found  in  in  vitro  studies  recently  published  by  Yannielli  and  Harrington  (2000).  In  these 
experiments,  phase  delays  to  light  were  blocked  by  NPY  application  to  the  SCN  slice 
preparation.  Because  of  these  apparent  discrepancies  in  the  literature  it  was  first  necessary 
46 for  me  to  examine  this  interaction  in  vivo  myself.  I  designed  my  experiments  to  closely 
mimic  the  drug  administration  times  of  those  preformed  in  vitro  by  other  groups. 
Furthermore,  I  also  start  to  examine  the  possible  site  of  interaction  between  NPY  and  light. 
I  aim  to  investigate  the  possible  NPY  receptor  subtype  utilized  by  NPY  in  its  interaction 
with  light.  It  is known  that  phase  shifts  to  NPY  during  the  mid-subjective  day  are 
mediated  via  the  Y2  receptor  subtype  (Huhman  et  al.,  1996;  Biello  et  al.,  1997b).  It  is 
thought  that  either  or  both,  the  Y1  and  Y5  receptor  subtypes,  are  involved  in  the  inhibition 
of  photic  phase  shifts.  In  these  experiments  I  used  a  specific  Y1/Y5  receptor  agonist  to 
determine  if  these  receptors  were  involved  in  the  complex  interaction  between  NPY  and 
light. 
Chapter  3 
Having  identified  that  NPY  interacts  with  photic  phase  shifts  via  either  or  both  the  Y1  and 
Y5  receptor  subtypes,  I  wanted  to  further  clarify  and  pinpoint  the  specific  receptor  utilized 
by  NPY  in  this  interaction.  Previously  this  was  difficult  due  to  the  commercial 
unavailability  of  a  specific  Y5  receptor  antagonist.  However,  we  were  very  fortunate  to 
obtain  samples  of  a  specific  Y5  antagonist  from  Johnson  and  Johnson  pharmaceuticals.  In 
this  experiment  I  used  specific  Y1  and  Y5  receptor  antagonists  to  identify  the  NPY 
receptor  involved  in  the  interaction  between  NPY  and  light. 
Chapter  4 
It  was  found  that  the  NPY  Y5  receptor  subtype  was  utilized  by  NPY  in  the  inhibition  of 
light  induced  phase  shifts.  Phase  advances  to  NPY  have  been  shown  to  involve  a 
47 GABAergic  mechanism  indicating  NPY  shifts  are  mediated  via  the  GABAA  receptor 
(Hufiman  et  al.,  1995). 
Here  I  examine  if  NPY  utilizes  a  similar  GABAA-dependent  pathway  in  the  inhibition  of 
photic  phase  shifts. 
Chapter  5 
My  previous  experiments  have  shown  that  NPY  interacts  with  light  via  the  activation  of 
the  Y5  receptor  subtype  and  through  a  pathway  independent  of  GABAA  receptor 
activation.  Taken  together  it  is  likely  that  the  site  of  interaction  lies  within  SCN  cells, 
downstream  from  receptor  binding  sites. 
In  these  experiments  I  examine  the  limitations  of  the  inhibitory  actions  of  NPY  on  light 
induced  phase  advances.  I  use  NPY  microinjections,  which  are  administered  in  a  time 
course  manner  post  light  exposure.  Furthermore,  I  also  run  experiments  using  a  classic 
non-photic  stimulus,  the  novel  running  wheel.  In  these  studies  animals  receive  this 
behavioral  stimulus  instead  of  NPY  microinjections  in  the  same  time  dependent  manner  as 
NPY  administration. 
An  important  long-term  goal  of  research  on  biological  rhythms  is  to  aid  the  understanding 
and  treatment  of  circadian  related  disorders  in  humans.  Both  photic  and  non-photic  cues 
play  a  vital  role  in  our  everyday  lives.  The  integration  of  these  stimuli  allows  our 
physiological  processes  to  function  in  such  a  way  that  they  all  act  to  regulate  and  maintain 
an  internal  homeostatic  environment. 
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Attenuation  of  circadian  light  induced  phase  advances  and  delays  by 
neuropeptide  Y  and  a  neuropeptide  Y  Yl/Y5  receptor  agonist. 
Interactions  between  light  and  NPY  were  investigated  during  the  early  (two  hours  after 
activity  onset)  and  late  (six  hours  after  activity  onset)  night  in  male  Syrian  hamsters. 
Neuropeptide  Y  microinjections  into  the  region  of  the  SCN  significantly  attenuated  light 
induced  phase  delay,  during  the  early  subjective  night.  Phase  advances  to  light  were 
completely  inhibited  by  the  administration  of  NPY  during  the  late  night. 
The  precise  mechanism  by  which  NPY  attenuates  or  blocks  photic  phase  shifts  is  unclear. 
The  NPY  Yl/Y5  receptor  agonist,  [Leu31,  Pro34]NPY,  was  administered  via  cannula 
microinjections  following  light  exposure  during  the  early  and  late  night.  [Leu31, 
Pro34]NPY  significantly  attenuated  phase  delays  to  light  during  the  early  night  and  blocked 
phase  advances  during  the  late  night,  in  a  manner  similar  to  NPY. 
These  results  show  the  ability  of  NPY  to  attenuate  phase  shifts  to  light  during  the  early 
night  and  block  light  induced  phase  advances  during  the  late  night.  Furthermore,  this  study 
implicates  the  involvement  of  the  NPY  Y1/Y5  receptors  in  the  complex  interaction  of 
photic  and  non-photic  stimuli  during  the  night. 
49 2.1  Introduction 
Injections  of  NPY  have  been  shown  to  induce  phase  shifts  similar  to  those  observed  with 
non-photic  stimuli  (Biello  et  al.,  1994)  and  subsequent  light  exposure  can  attenuate  these 
shifts  (Biello  and  Mrosovsky,  1995).  Neuropeptide  Y  phase  shifts,  in  vitro,  can  be  blocked 
by  the  administration  of  glutamate  (Biello  et  al.,  1997a),  the  major  neurotransmitter 
thought  to  be  involved  in  the  mediation  of  photic  information  to  the  SCN  (Ebling,  1996). 
Phase  shifts  to  light  during  the  late  phase  of  the  subjective  night  (the  active  phase  in 
nocturnal  rodents)  can  be  attenuated  by  NPY  (Weber  and  Rea,  1997)  or  potentiated  by 
antiserum  to  NPY  (Biello,  1995),  in  vivo.  A  recent  in  vivo-in  vitro  model  has  provided 
further  evidence  for  the  role  of  NPY  in  the  modulation  of  photic  influences  to  the  SCN 
(Yannielli  and  Harrington,  2000).  In  this  novel  paradigm,  light  pulses  were  presented  in 
vivo  followed  by  NPY  administration  in  vitro. 
The  current  study  was  designed  to  examine  the  effects  of  NPY  administration  on  photic 
phase  shifts  during  the  subjective  night,  in  vivo.  More  significantly  the  involvement  of  the 
NPY  Y1  and/or  NPY  Y5  receptors  were  investigated  in  the  mediation  of  the  attenuating 
effects  of  NPY  on  light  in  vivo,  during  the  early  and  late  night. 
50 2.2  Experimental  procedures 
2.2.1  Subjects 
Experimental  procedures  were  carried  out  under  licence  by  the  Home  Office  (UK)  in 
accordance  with  the  Animals  (Scientific  Procedures)  Act  (1986).  Adult  male  Syrian 
hamsters  (40  days  old,  Harlan  Sprague-Dawley,  Oxon,  UK)  were  housed  individually  in 
plastic  cages  fitted  with  16  cm  running  wheels  connected  to  a  computer  that  summed 
wheel  revolutions  in  10  minute  activity  bins  (Dataquest  Pro-Data  software,  Data  Sciences 
Inc.,  Roseville,  MN,  USA).  Food  and  water  were  available  ad  libitum.  Animals  (n=22) 
were  maintained  under  a  light-dark  (LD)  cycle  of  14  hours  light  and  10  hours  of  darkness 
and  then  transferred  to  constant  conditions  (22  ±  2°C;  14-18  lux  dim  red  light)  10  days 
before  treatment.  Animals  were  re-entrained  by  this  method  following  a  maximum  of 
three  treatments  before  continuing  with  further  experimental  conditions.  All  efforts  were 
made  to  minimize  the  number  of  animals  used  and  their  suffering. 
2.2.2  Surgery 
See  appendix  I  for  a  detailed  description  of  the  surgical  procedure. 
Hamsters  were  anaesthetised  with  halothane  gas  throughout  the  length  of  the  surgery. 
Animals  received  cannula  guides,  which  were  implanted  to  a  depth  of  5.1mm  below  the 
skull  surface  and  fixed  to  the  skull  with  fine  machine  screws  and  dental  cement.  Cannula 
guides  were  stereotaxically  aimed  at  the  third  ventricle,  just  above  the  SCN  (co-ordinates 
relative  to  bregma:  AP+0.6mm,  ML  0.1mm,  upper  incisor  bar  -2  mm).  After  recovery 
from  surgery  (1  week  under  LD  14:  1Oh),  animals  were  transferred  into  cages  fitted  with 
running  wheels  and  maintained  for  7-10  days  under  LD  14:  1  Oh  before  being  placed  into 
constant  conditions.  Porcine  NPY  (Calbiochem,  UK)  and  the  Y1/Y5  agonist  [Leu31, 
51 Pro34]NPY  (Sigma,  UK)  were  administered  using  a  28  gauge  infusion  cannula  attached  to  a 
I  µl  Hamilton  syringe  at  a  concentration  of  1  ng/nl  at  a  volume  of  200n1.  The  infusion 
cannula  extended  2.4  mm  from  the  base  of  the  guide  cannula. 
Neuropeptide  Y  and  [Leu31,  Pro34]NPY  were  dissolved  in  artificial  cerebral  spinal  fluid 
(ACSF;  in  mM;  NaC1124,  KCI  33,  KH2PO41.2,  CaC12  2.5,  MgSO41,  NaHCO3  2.5, 
glucose  10).  The  vehicle  consisted  of  ACSF  only. 
2.2.3  Experimental  treatments 
Prior  to  the  start  of  the  experiment  all  animals  in  group  1  were  injected  with  NPY  at  CT  6 
five  days  after  being  placed  into  constant  conditions.  Similarly  6  animals  in  group  2  were 
also  injected  with  NPY  at  CT  6  and  4  animals  were  injected  with  GRP  (150pmol,  200n1, 
dissolved  in  ACSF).  These  microinjections  were  used  as  functional  assessments  to  verify 
cannula  placements. 
Group  1  (n=12)  hamsters  completed  the  following  sequence  of  treatments:  (1)  a  15  minute 
light  pulse  (130  lux)  at  CT14,  (2)  NPY  administration  at  CT14,  (3)  a  15  minute  light  pulse 
at  CT14  in  combination  with  NPY  administration  at  CT14.25,  (4)  [Leu31,  Pr034]NPY 
administration  at  CT  14,  (5)  a  15  minute  light  pulse  at  CT14  followed  by  [Leu31,  Pro34]NPY 
administration,  (6)  administration  of  the  vehicle  at  CT14,  (7)  a  15  minute  light  pulse  at 
CT14  directly  followed  by  vehicle  administration. 
Group  2  (n=10)  hamsters  completed  the  following  sequence  of  treatments:  (1)  a  15  minute 
light  pulse  (130  lux)  at  CT  18,  (2)  NPY  administration  at  CT18,  (3)  a  15  minute  light  pulse 
52 at  CT18  in  combination  with  NPY  administration  at  CT18.25,  (4)  [Leu31,  Pro34]NPY 
administration  at  CT18,  (5)  a  15  minute  light  pulse  at  CT18  followed  by  [Leu31,  Pro34]NPY 
administration,  (6)  administration  of  the  vehicle  at  CT  18,  (7)  a  15  minute  light  pulse  at 
CT18  directly  followed  by  vehicle  administration. 
2.2.4  Data  analysis 
For  activity  onset  calculation  see  appendix  III. 
Data  from  each  set  of  treatments  was  analysed  by  the  one-way  repeated  measures 
ANOVA,  followed  by  Bonferroni's  method  for  multiple  comparisons.  All  t-values 
reported  were  derived  from  multiple  comparison  tests. 
2.2.5  Cannula  Placement 
See  appendix  IV  for  cannula  placement  assessment  methods. 
53 2.3  Results 
2.3.1  Effects  of  [Leu  31,  PrO34JNPY  and  NPY  on  light  induced  phase  delays 
Light  stimulation  at  CT  14  resulted  in  phase  shifts  of  -93  ±7  minutes  (mean  ±  SEM). 
Phase  delays  to  light  were  attenuated  by  microinjection  of  NPY  directly  after  photic 
stimulation  with  phase  shifts  of-37  ±9  minutes  (F(5,55j=  25.2,  p<0.01).  Furthermore  the 
administration  of  the  NPY  Yl/Y5  receptor  agonist,  [Leu31,  Pro34]NPY,  following  light 
exposure  also  resulted  in  the  attenuation  of  light  induced  phase  shifts  (-49  ±8  minutes; 
t-4.25,  p<0.05).  The  combination  of  light  and  NPY  administration  was  not  significantly 
different  from  NPY  microinjection  alone  (t=  1.60,  p>0.05),  however  it  was  significantly 
different  from  light  followed  by  vehicle  treatment  (-91  ±6  minutes,  t=  5.45,  p>0.05). 
Neuropeptide  Y  or  [Leu31,  Pro34]NPY  produced  phase  shifts  of  -19  ±8  minutes  and  -7  ±6 
minutes  respectively.  Phase  shifts  to  light  were  not  significantly  altered  by  vehicle 
administration  post  light  exposure  (t=0.14,  p>0.05). 
2.3.2  Effects  of  [Leu  31,  Pro34]NPY  and  NPY  on  light  induced  phase  advances 
Light  induced  phase  advances  (124  ±8  minutes)  were  blocked  by  the  administration  of 
[Leu31,  Pro34]NPY  and  NPY  with  resulting  phase  shifts  of  -5  ±  12  minutes  and  7±  15 
minutes  respectively  (F(6148)=  34.7,  p<0.01).  Microinjections  of  NPY  or  [Leu31,  Pro34]NPY 
alone  resulted  in  phase  shifts  of  6±  15  minute  and  7±6  minutes  respectively.  Vehicle 
administration  following  light  stimulation  did  not  result  in  phase  shifts  significantly 
different  from  those  with  light  exposure  alone  (106  ±  4;  t=1.42,  p>0.05). 
54 2.3.3  Extended  inhibition  of  activity  by  light  pulses 
Pulses  of  light  at  CT  14  resulted  in  the  attenuation  of  activity  compared  to  levels  during 
prepulse  days  at  the  same  CT  time  (t=5.53,  p<0.05;  Fig.  3).  This  extended  inhibition 
following  15  minutes  of  light  exposure  lasted  for,  on  average,  117  ±  19  minutes.  The 
duration  of  quiescence  following  light  stimulation  was  defined  as  the  time  until  at  least  one 
wheel  revolution  was  recorded  in  each  of  three  successive  10  minute  bins  (Mistlberger  and 
Antle,  1998).  The  combination  of  light  with  NPY  or  [Leu31,  Pro34]NPY  resulted  in  a 
shortening  of  this  extended  inhibition  due  to  light  alone  (52  ±  16  and  50  ±  16  minutes 
respectively,  F(s,  50)=  8.59,  p<0.01). 
Pre-pulse  days  showed  minimal  activity  levels  during  the  late  subjective  night,  therefore 
light  pulses  at  CT  18  did  not  significantly  attenuate  home  cage  wheel  running.  During  the 
hour  following  light  exposure,  NPY  or  [Leu  31,  Pro34]NPY  microinjections  or  a  combination 
of  light  and  either  NPY  or  [Leu31,  Pro34]NPY  wheel  running  activity  was  not  significantly 
suppressed  compared  with  control  days  i.  e.  pre-pulse  days  (F(9,90ý=  6.3  3,  p<0.01). 
2.3.4  Effects  on  Tau 
The  administration  of  light,  NPY,  [Leu31,  Pro34]NPY  or  a  combination  of  light  and  NPY  or 
[Leu  31,  Pro34]NPY  did  not  significantly  alter  tau  (p>0.05),  both  during  the  early  and  late 
subjective  night.  These  findings  reflect  those  from  previous  studies  (Biello  et  al.,  1994). 
2.3.5  Cannula  placement  verification 
For  functional  assessment  animals  were  injected  with  a  known  phase  shifting  stimulus.  All 
phase  shifts  seen  in  this  experimental  group  were  comparable  to  those  obtained  in  previous 
studies  (Piggins  et  al.,  1995;  Biello  and  Mrosovsky,  1996;  Mintz  et  al.,  1999;  McArthur  et 
55 al.,  2000).  The  following  stimuli  were  used  for  functional  assessment:  NPY  injected  at  CT 
6  (200n1  at  a  concentration  of  ing/n1,133  min  ±  9.6  [mean  ±  SEM],  n=10);  GRP  injected 
at  CT  14  (150pmol,  200n1,  -191.1min  ±  21.2,  n=4).  Further,  histological  placement 
verification  confirmed  that  cannula  were  within  400µm  of  the  SCN  along  the  anterior- 
posterior,  dorsal-ventral  and  lateral  axes. 
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57 Figure  8.  Phase  delays  to  light  were  significantly  attenuated  by  the  administration  of 
[Leu31,  Pro34]NPY,  a  NPY  Y1/Y5  receptor  agonist  and  NPY  (Light  +  Agonist  and  Light  + 
NPY  respectively;  p<0.05).  Microinjections  of  NPY  or  [Leu31,  Pro34]NPY  resulted  in 
minimal  phase  delays  (NPY  and  Agonist  respectively).  Vehicle  administration  post  light 
exposure  (Light  +  Vehicle)  had  no  effect  on  the  phase  shifting  properties  of  light  at  this 
time. 
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59 
Light  +  NPY  Agonist  Light  +  Agonist Figure  9.  Light  induced  phase  advances  were  blocked  by  microinjections  of 
[Leu31,  Pro34]NPY  and  NPY  (Light  +  Agonist  and  Light  +  NPY  respectively;  p<0.05). 
Little  effect  on  phase  was  observed  with  administration  of  [Leu31,  Pro34]NPY  or  NPY  alone 
(Agonist  and  NPY  respectively).  No  significant  effect  on  light  induced  phase  shifts  was 
observed  by  the  administration  of  the  vehicle  post  light  exposure  (Light  +  Vehicle, 
p>0.05). 
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61 Figure  10.  Representative  actograms  demonstrating  the  attenuation  of  light  induced  phase 
delays  at  CT  14  by  [Leu31,  Pro34]NPY  and  NPY.  Light  exposure  for  15  minutes  at  CT  14 
resulted  in  a  phase  delays  of  the  free  running  rhythm  in  Syrian  hamsters.  However 
microinjections  of  either  [Leu  31,  Pro34]NPY  or  NPY,  at  the  end  of  the  light  pulse,  were  able 
to  attenuate  these  phase  shifts.  Times  of  light  stimulation  are  indicated  by  inverted  open 
triangles. 
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63 Figure  11.  Representative  actograms  demonstrating  the  inhibition  of  light  induced  phase 
advances  at  CT  18  by  [Leu  31,  Pro34]NPY  and  NPY.  Phase  advances  to  light  were  blocked 
by  the  administration  of  [Leu31,  Pro34]NPY  or  NPY.  Times  of  light  stimulation  are 
indicated  by  inverted  open  triangles. 
64 2.4  Discussion 
The  current  study  demonstrates  the  inhibitory  effects  of  NPY  on  light  induced  phase  shifts 
during  the  subjective  night,  in  vivo.  Microinjections  of  NPY  were  shown  to  attenuate  light 
induced  phase  delays  for  the  first  time;  furthermore  NPY  administration  blocked  phase 
advances  to  light  during  the  late  subjective  night.  Finally,  and  most  significantly,  the  NPY 
Y1/Y5  receptor  agonist,  [Leu31,  Pro34]NPY,  was  found  to  attenuate  phase  delays  and  block 
advances  to  light,  in  a  manner  similar  to  NPY. 
Phase  advances  to  light  were  attenuated  by  approximately  90%  after  administration  of 
NPY  during  the  late  subjective  night  in  our  current  study.  However  phase  delays  to  light 
showed  only  a  40%  attenuation  after  administration  of  NPY.  This  variation  in  results 
between  the  early  and  late  night  may  be  due  to  the  difference  in  the  way  light  resets  the 
clock  during  these  times.  Glutamate  is  thought  to  be  the  principal  neurotransmitter 
responsible  for  relaying  photic  information  to  the  SCN.  The  presence  of  glutamate  in 
presynaptic  terminals  of  the  SCN  has  been  shown  using  ultrastructural  methods  (Ebling, 
1996).  Stimulation  of  the  optic  nerve  in  vitro,  releases  glutamate  onto  SCN  cells  (Liou  et 
al.,  1986),  while  optic  nerve  stimulation  in  vivo  produces  phase  shifts  that  mimic  those 
seen  in  response  to  light  (de  Vries  et  al.,  1994).  In  vitro  investigations  have  shown 
glutamate  induced  phase  shifts  to  be  blocked  by  NPY  administration  during  the  early  and 
late  night  (Biello  et  al.,  1997a).  Recently,  phase  shifts  to  the  glutamatergic  agonist  N- 
methyl-D-aspartate  (NMDA)  in  vitro,  were  blocked  by  the  administration  of  NPY  during 
the  early  night  (Yannielli  and  Harrington,  2001). 
65 Light  and  glutamate  phase  shift  the  SCN  mainly  via  NMDA  receptors  during  the  early 
subjective  night  (Ding  et  al.,  1998)  and  via  a  mechanism  involving  protein  kinase  G  (PKG) 
during  the  late  subjective  night  (Weber  et  al.,  1995).  It  is  possible  that  the  activation  of  the 
NMDA  receptor  results  in  a  more  rapid  induction  of  the  intracellular  pathway  mediating 
the  resetting  of  the  clock  than  that  initiated  by  PKG  activation.  However,  the  inhibitory 
action  of  NPY  may  remain  consistent  between  the  early  and  late  night,  hence  the  ability  of 
NPY  to  attenuate  light  induced  phase  shifts  may  be  determined  by  the  speed  at  which  the 
glutamatergic  intracellular  pathway  proceeds. 
Hamsters  maintained  under  constant  conditions  for  long  periods  of  time  do  show  greater 
responses  to  photic  stimuli  (Shimomura  and  Menaker,  1994).  To  minimize  this  effect  our 
animals  were  re-entrained  to  a  light-dark  cycle  following  a  maximum  of  three  treatments. 
A  previous  study  conducted  by  Weber  and  Rea  (1997)  found  NPY  microinjections  blocked 
phase  advances  to  light,  but  did  not  significantly  alter  phase  delays.  There  were  several 
methodological  differences  that  may  account  for  the  attenuation  of  our  photic  phase  delay 
shifts  reaching  significance.  First,  cannula  guides  were  aimed  at  the  SCN  in  the  Weber  & 
Rea  study,  while  our  cannula  guides  were  aimed  at  the  third  ventricle,  just  above  the  SCN. 
Thus,  it  is  possible  that  NPY  may  be  acting  at  a  site  other  than  that  of  the  SCN  in  our 
study  although  unlikely  due  to  in  vitro  evidence.  Also,  NPY  administration  times  also 
differed,  with  Weber  and  Rea  microinjecting  10  minutes  prior  to  light  stimulation.  The 
administration  of  NPY  prior  to  the  light  pulse  may  have  induce  induced  physiological 
changes  which  altered  the  way  photic  information  was  conveyed  to  the  SCN.  There  is 
support  for  this,  as  application  of  NPY,  to  rat  SCN  slices,  prior  to  treatment  with  NMDA, 
resulted  in  the  potentiation  of  NMDA  induced  phase  shift  (Shibata  et  al.,  1994).  However, 
66 another  in  vitro  study  showed  that  NPY  administration  following  NMDA  treatment 
attenuated  the  phase  shift  (Yannielli  and  Harrington,  2001). 
The  IGL  utilises  NPY  as  its  primary  neurotransmitter  (Harrington,  1997).  Microinjections 
of  anti-serum  raised  against  NPY  resulted  in  the  potentiation  of  light  induced  phase  shifts 
(Biello,  1995),  indicating  the  involvement  of  NPY  in  the  mediation  of  photic  stimuli  to  the 
SCN.  Lesions  to  the  GHT  have  been  shown  to  increase  light  induced  phase  delays 
(Pickard  et  al.,  1987),  implicating  the  role  of  the  IGL  and  NPY  in  the  regulation  of  photic 
phase  shifts.  Immunoassay  studies  have  shown  NPY  levels  to  peak  between  CT  12  and  CT 
14  under  constant  conditions,  in  rats  (Shinohara  et  al.,  1993).  Our  results  would  suggest 
that  the  endogenous  NPY  release  during  the  early  subjective  night  sub-maximally  saturates 
the  NPY  receptors  at  this  time;  hence  NPY  microinjections  were  only  able  to  attenuate  the 
phase  shift  to  light.  It  is  also  possible  that  at  CT  14  the  cells  of  the  SCN  are  less 
responsive  to  NPY  due  to  the  cycling  rhythm  of  this  neurotransmitter.  Therefore  only  a 
minimal  effect  of  NPY  microinjection  is  seen  on  photic  phase  delay  shifts  in  comparison  to 
the  late  subjective  night. 
Changes  in  the  free-running  period  of  hamsters  following  GHT  lesions  have  been  variable. 
One  group  reported  a  lengthening  of  the  free-running  period  following  GHT  lesions 
(Pickard  et  al.,  1987),  however  another  report  indicated  no  change  (Harrington  and  Rusak, 
1986).  Microinjections  of  NPY  alone  also  do  not  show  alterations  in  the  free-running 
rhythm  of  hamsters  (Biello  et  al.,  1994).  We  show  that  microinjections  of  NPY  or  the 
NPY  Y1/Y5  receptor  agonist  either  in  combination  with  light  or  alone  did  not  alter  the 
67 free-running  rhythm  in  our  hamsters,  suggesting  that  NPY  is  only  acting  as  a  direct 
inhibitor  to  light  and  not  influencing  the  natural  free  running  rhythm. 
Light  has  been  known  to  acutely  suppress  activity  in  nocturnal  rodents,  therefore 
`masking'  the  phase  of  the  circadian  pacemaker  (Aschoff  et  al.,  1982).  Pulses  of  light  at 
CT  14  resulted  in  the  suppression  of  activity  for  approximately  100  minutes,  however  the 
co-application  of  NPY  or  [Leu31,  Pro34]NPY  reduced  this  suppression  by  approximately 
50%.  It  is  possible  that  NPY  influences  photic  phase  shifts  by  reducing  the  duration  of  the 
suppression  in  activity  induced  by  light.  Hence  supporting  a  role  of  NPY  in  the  induction 
of  activity. 
At  least  three  NPY  receptor  subtypes  have  been  found  in  the  SCN,  NPY  Y1,  NPY  Y2  and 
NPY  Y5  receptors  (Chen  and  van  den  Pol,  1996;  Golombek  et  al.,  1996;  Larsen  and 
Kristensen,  1998).  Phase  shifts  induced  by  NPY  are  mediated  by  the  NPY  Y2  receptor 
(Golombek  et  al.,  1996;  Hufiman  et  al.,  1996).  However,  it  is  likely  that  the  regulation  of 
photic  entrainment  by  NPY,  may  involve  the  NPY  Y1  or  NPY  Y5  receptor  subtypes.  Due 
to  the  lack  of  commercially  available  specific  NPY  Y1  or  NPY  Y5  receptor  agonists  and 
antagonists  we  were  unable  to  determine  the  relative  contribution  of  either  receptor  in  the 
inhibition  of  photic  phase  shifts.  This  is  certainly  an  area  on  which  to  focus  future  in  vivo 
work. 
At  the  level  of  gene  expression,  light  stimulation  results  in  the  increase  of  Perl  and  Per2 
mRNA  levels  (mPerl  and  mPer2,  respectively),  in  mice  (Shearman  et  al.,  1997;  Zylka  et 
al.,  1998).  Light  induced  phase  delays  have  been  strongly  linked  to  increases  in  mPer2, 
68 while  phase  advances  to  increases  in  mPerl,  in  the  mouse  (Albrecht  et  al.,  2001). 
However,  NPY  administration  has  been  shown  to  reduce  mPerl  and  mPer2  levels  in 
hamsters  and  mice  (Fukuhara  et  al.,  2001;  Maywood  et  al.,  2002).  In  the  early  night  NPY 
differentially  suppresses  mPerl  and  mPer2  levels  after  light  stimulation,  such  that  there  is 
a  sustained  suppression  of  mPer2  (Brewer  et  al.,  2002).  It  is  possible  that  alternate 
differential  suppression  of  mPerl  and  mPer2  late  in  the  night  could  explain  the  observed 
differences  in  photic  suppression. 
The  modulation  of  light  induced  phase  shifts  by  NPY  is  possibly  a  vital  mechanism  in  the 
ability  of  mammals  to  synchronise  to  the  environmental  light  dark  cycle.  We  have  shown 
NPY  to  attenuate  both  phase  delays  and  inhibit  phase  advances  to  light  during  the 
subjective  night,  in  vivo.  Furthermore  our  results  show,  for  the  first  time,  that  NPY 
suppresses  both  photic  phase  advances  and  delays  via  the  NPY  Y1  and/or  the  Y5  receptors, 
in  vivo. 
69 Chapter  3 
Neuropeptide  Y  inhibits  photic  phase  shifts  via  the  Y5  receptor. 
In  the  previous  chapter  it  was  shown  that  NPY  utilized  either  or  both  the  Y1  or  Y5  receptor 
subtypes  in  its  interaction  with  photic  phase  shifts.  Due  to  the  commercial  unavailability 
of  a  specific  Y5  receptor  antagonist  a  Y1/Y5  agonist  was  used  in  the  previous  study. 
Recently,  Johnson  and  Johnson  pharmaceuticals  have  developed  a  Y5  receptor  antagonist. 
We  were  fortunate  to  receive  adequate  samples  of  this  novel  drug  to  test,  in  vivo. 
The  administration  of  the  Y5  receptor  antagonist  during  light  exposure  followed  by  NPY 
administration  prevented  the  attenuation  of  the  photic  phase  shift  by  NPY  during  the  early 
and  late  subjective  night.  Furthermore,  microinjections  of  a  specific  Y1  receptor 
antagonist  did  not  influence  the  inhibitory  actions  of  NPY  on  light  induced  phase  advances 
and  delays. 
This  study  clearly  indicates  that  NPY  utilizes  the  Y5  receptor  subtype  in  its  interaction 
with  light  during  both  the  early  and  late  subjective  night. 
70 3.1  Introduction 
The  precise  mechanism  by  which  NPY  mediates  its  modulatory  effects  on  photic  stimuli  is 
unclear.  However  a  variety  of  NPY  receptor  subtypes  have  been  found  to  mediate  effects 
of  NPY  on  pacemaker  cells.  Rat  SCN  has  been  shown  to  express  NPY  Y1  (Y1),  NPY  Y2 
(Y2)  and  NPY  Y5  (Y5)  receptor  subtypes  (Weinberg  et  al.,  1996;  Larsen  and  Kristensen, 
1998).  The  phase  resetting  effects  of  NPY  during  the  day  were  found  to  be  mediated  via 
the  Y2  receptor  subtype  (Golombek  et  al.,  1996;  Huhman  et  al.,  1996).  In  vivo  work 
indicates  that  either  or  both  the  Y1  and  Y5  receptors  are  involved  in  the  interaction 
between  light  and  NPY  during  the  night  (Lall  and  Biello,  2003b).  In  this  case  a  specific 
Y1/Y5  receptor  agonist  attenuated  phase  delays  to  light  and  inhibited  phase  advances  in  a 
similar  manner  to  NPY  microinjections.  Furthermore,  phase  shifts  to  NMDA  were 
blocked  by  NPY  administration  in  vitro  and  this  inhibition  was  prevented  by  the 
application  of  a  specific  Y5  receptor  antagonist  prior  to  NPY  microinjection  (Yannielli  and 
Harrington,  2001). 
Thus,  it  is  possible  that  NPY  mediates  its  inhibitory  effect  on  photic  stimuli  via  either  or 
both  the  Y1  or  Y5  receptor  subtypes  in  vivo  and  in  vitro.  The  current  study  was  designed 
to  determine  the  precise  receptor  or  receptors  utilized  by  NPY  in  its  complex  interaction 
with  light,  in  vivo. 
71 3.2  Materials  and  methods 
3.2.1  Subjects 
Experimental  procedures  were  carried  out  under  licence  by  the  Home  Office  (UK)  in 
accordance  with  the  Animals  (Scientific  Procedures)  Act  (1986).  Adult  male  Syrian 
hamsters  (40  days  old,  Harlan  Sprague-Dawley,  Oxon,  UK)  were  housed  individually  in 
plastic  cages  fitted  with  16  cm  running  wheels  connected  to  a  computer  that  summed 
wheel  revolutions  in  10  minute  activity  bins  (Dataquest  Pro-Data  software,  Data  Sciences 
Inc.,  Roseville,  MN,  USA).  Food  and  water  were  available  ad  libitum.  Animals  (n=21) 
were  maintained  under  a  LD  cycle  of  14  hours  light  and  10  hours  of  darkness  and  then 
transferred  to  constant  conditions  (22  ±  2°C;  14-18  lux  dim  red  light)  10  days  before 
treatment.  Animals  were  re-entrained  by  this  method  following  a  maximum  of  three 
treatments  before  continuing  with  further  experimental  conditions.  All  efforts  were  made 
to  minimise  the  number  of  animals  used  and  their  suffering. 
3.2.2  Surgery  and  injections 
See  appendix  I  for  a  detailed  description  of  the  surgical  procedure. 
Hamsters  were  anaesthetised  with  halothane  gas  throughout  the  length  of  the  surgery. 
Animals  received  cannula  guides,  which  were  implanted  to  a  depth  of  5.6mm  below  the 
skull  surface  at  a  10°  angle  and  fixed  to  the  skull  with  fine  machine  screws  and  dental 
cement.  Cannula  guides  were  stereotaxically  aimed  at  the  SCN  (co-ordinates  relative  to 
bregma:  AP+0.4mm,  ML  1.0mm,  upper  incisor  bar  -2  mm).  After  recovery  from  surgery 
(1  week  under  LD  14:  1Oh),  animals  were  transferred  into  cages  fitted  with  running  wheels 
and  maintained  for  7-10  days  under  LD  14:  1Oh  before  being  placed  into  constant 
conditions.  In  all  treatments  the  vehicle  consisted  of  a  0.9%  saline  solution.  Porcine  NPY 
72 (234µM  in  200n1  saline,  Calbiochem,  UK),  Y1  antagonist  BIBP  3226  BS  (R-N2- 
(diphenylacetyl)-N-(4-hydroxyphenyl)-methyl-argininamide;  1  µM  in  200n1  saline; 
Research  Biochemicals)  and  Y5  antagonist  RWJ57926  ([a-(3-pyridylmethyl)-(3- 
aminotetralin-derived  sulfonamide];  2µM  in  200nl  saline;  RW  Johnson  Pharmaceutical 
Research  Institute),  were  administered  using  a  28  gauge  infusion  cannula  attached  to  a1  µl 
Hamilton  syringe.  The  infusion  cannula  extended  2.4  mm  from  the  base  of  the  guide 
cannula. 
3.2.3  Experimental  treatments 
Prior  to  the  start  of  the  experiment  all  animals  were  injected  with  NPY  at  CT  6  five  days 
after  being  placed  into  constant  conditions.  These  microinjections  were  used  as  functional 
assessments  to  verify  cannula  placements. 
Experiment  1  (n=10).  Hamsters  completed  the  following  sequence  of  treatments:  (1)  a  15 
minute  light  pulse  (130  lux)  at  CT14  directly  followed  by  vehicle  administration,  (2)  saline 
administration  at  CT14  followed  by  NPY  administration  at  CT14.08,  (3)  Y1  antagonist 
administration  at  CT14  followed  by  saline  administration  at  CT14.08,  (4)  Y5  antagonist 
administration  at  CT14  followed  by  saline  administration  at  CT14.08,  (5)  a  15  minute 
light  pulse  at  CT14  with  Y1  antagonist  administration  at  CT14.08  and  NPY  administration 
at  CT14.17,  (6)  a  15  minute  light  pulse  at  CT14  with  Y5  antagonist  administration  at 
CT14.08  and  NPY  administration  at  CT14.17,  (7)  a  15  minute  light  pulse  at  CT14  with  Y1 
antagonist  administration  at  CT14.08  and  saline  administration  at  CT14.17,  (8)  a  15  minute 
light  pulse  at  CT14  with  Y5  antagonist  administration  at  CT14.08  and  saline 
73 administration  at  CT14.17,  (9)  a  15  minute  light  pulse  at  CT14  with  saline  administration 
at  CT14.08  and  NPY  administration  at  CT14.17. 
Experiment  2  (n=9).  Hamsters  completed  the  following  sequence  of  treatments:  (1)  a  15 
minute  light  pulse  (130  lux)  at  CT18  directly  followed  by  vehicle  administration,  (2)  saline 
administration  at  CT  18  followed  by  NPY  administration  at  CT18.08,  (3)  Y1  antagonist 
administration  at  CT18  followed  by  saline  administration  at  CT18.08,  (4)  Y5  antagonist 
administration  at  CT18  followed  by  saline  administration  at  CT18.08,  (5)  a  15  minute 
light  pulse  at  CT18  with  Y1  antagonist  administration  at  CT  18.08  and  NPY  administration 
at  CT18.17,  (6)  a  15  minute  light  pulse  at  CT18  with  Y5  antagonist  administration  at 
CT  18.08  and  NPY  administration  at  CT  18.17,  (7)  a  15  minute  light  pulse  at  CT  18  with  Y1 
antagonist  administration  at  CT18.08  and  saline  administration  at  CT18.17,  (8)  a  15  minute 
light  pulse  at  CT18  with  Y5  antagonist  administration  at  CT18.08  and  saline 
administration  at  CT18.17,  (9)  a  15  minute  light  pulse  at  CT18  with  saline  administration 
at  CT18.08  and  NPY  administration  at  CT18.17. 
3.2.4  Data  analysis 
For  activity  onset  calculation  see  appendix  III. 
Data  from  each  set  of  treatments  was  analysed  by  the  one-way  repeated  measures 
ANOVA,  followed  by  Student-Newman-Keuls  method  for  multiple  comparisons.  All  t- 
values  reported  were  derived  from  multiple  comparison  tests. 
74 3.2.5  Cannula  Placement 
See  appendix  IV  for  cannula  placement  assessment  methods. 
75 3.2  Results 
3.3.1  Effects  of  BIBP  3226  on  the  attenuation  of  photic  phase  delays  by  NPY 
The  administration  of  the  specific  Y1  receptor  antagonist  during  light  exposure  and 
preceding  NPY  microinjection  did  not  significantly  alter  the  ability  of  NPY  to  attenuate  the 
photic  phase  shift  with  delays  of  -29  ±5  minutes  (mean  ±  S.  E.  M)  in  the  presence  of  the 
Y1  antagonist  and  -38  ±5  minutes  with  a  vehicle  substitution  of  BIBP  3226  (p>0.05,  fig. 
12).  Injections  of  the  Y1  antagonist  during  light  exposure  followed  by  saline 
microinjection  did  not  alter  phase  shifts  to  the  photic  stimulus  at  this  time  with  resulting 
shifts  of  -58  ±5  minutes  and  -64  ±6  minutes  with  light  and  saline  administration  alone 
(p>o.  O5). 
Neuropeptide  Y  administration  following  light  exposure  resulted  in  the  attenuation  of  the 
photic  phase  shift  observed  with  light  and  saline  with  average  shifts  of  -38  ±5  minutes  and 
-64  ±6  minutes  respectively  (p<0.01).  Microinjections  of  NPY  followed  by  saline  or 
BIBP  3226  and  saline  resulted  in  shifts  that  were  not  significantly  different  from  each  other 
(-13  ±6  minutes  and  0±4  minutes  respectively;  p>0.05),  but  both  were  significantly 
different  from  phase  shifts  resulting  from  light  and  saline  treatment  (F(8,81)=  29.1;  fig.  14). 
3.3.2  Effects  of  RWJ57926  on  the  attenuation  of  photic  phase  delays  by  NPY 
Microinjection  of  the  specific  Y5  receptor  antagonist  prevented  the  attenuation  of  the 
photic  phase  delay  by  NPY  (-74  ±5  minutes)  with  shifts  significantly  different  from  those 
observed  with  saline  substituted  for  the  Y5  antagonist  at  this  time  (p<0.001,  fig.  12). 
However  administration  of  RWJ57926  during  light  exposure  followed  by  saline  injection 
76 did  not  significantly  alter  the  light  induced  phase  shift  with  resulting  shifts  of  -72  ±8 
minutes  relative  to  -65  ±6  minutes  with  light  and  saline  alone  (p>0.05). 
The  injection  of  RWJ57926  followed  by  saline  resulted  in  phase  shifts  not  significantly 
different  from  those  with  NPY  and  saline,  with  shifts  of  -3  ±4  minutes  and  -12.9  ±6 
minutes  respectively  (p>0.05). 
3.3.3  Effects  of  BIBP  3226  on  the  inhibition  of  photic  phase  advances  by  NPY 
Light  presented  at  CT  18  followed  by  saline  administration  resulted  in  phase  shifts  of  106 
±4  minutes.  These  shifts  were  inhibited  by  NPY  microinjection  post  light  exposure  with 
resulting  shifts  of  7±  15  minutes  (p<0.001).  The  administration  of  the  specific  Y1 
receptor  antagonist  during  the  photic  pulse  followed  by  NPY  microinjection  did  not 
significantly  alter  the  inhibitory  effect  of  NPY  with  average  shifts  of  11  ±9  minutes 
(p>0.05).  Furthermore,  the  presence  of  the  Y1  antagonist  did  not  influence  the  phase 
shifting  effects  of  light  (119  ±4  minutes),  with  shifts  not  significantly  different  from  light 
and  saline  administration  (p>0.05). 
Microinjections  of  BIBP  3226  and  saline  resulted  in  phase  shifts  similar  to  those  observed 
with  NPY  and  saline  administration,  with  average  shifts  of  8±1  minutes  and  7±  15 
minutes  respectively  (p>0.05). 
3.3.4  Effects  of  RWJ57926  on  the  inhibition  of  photic  phase  advances  by  NPY 
Administration  of  the  Y5  receptor  antagonist  inhibited  the  blocking  effects  of  NPY  on  light 
induced  phase  advances.  Phase  shifts  to  light,  followed  by  RWJ57926  and  NPY 
77 administration  resulted  in  advances  of  166  ±  10  minutes,  which  were  significantly  different 
from  those  observed  with  light,  saline  and  NPY  administration  (8  ±  15  minutes;  p<0.001). 
Furthermore,  both  treatment  groups  receiving  the  Y5  antagonist  with  light  and  either  NPY 
or  saline  (170  ±  11  minutes)  showed  shifts  greater  than  those  observed  with  light  and  saline 
(106  ±4  minutes)  alone  (p<0.001,  in  both  instances). 
Phase  shifts  to  light,  RWJ57926  and  NPY  were  not  significantly  different  from  those 
obtained  with  light,  RWJ57926  and  saline  administration  (p>0.05).  Microinjections  of  the 
Y5  antagonist  and  saline  resulted  in  phase  shifts  that  were  not  significantly  different  from 
those  with  NPY  and  saline  treatments,  with  average  shifts  of  3±2  minutes  and  7±  15 
minutes,  respectively  (F(B,  72ý=  58.9;  p>0.05). 
3.3.5  Cannula  placement  verification 
For  functional  assessment  animals  were  injected  with  a  known  phase  shifting  stimulus.  All 
phase  shifts  seen  in  this  experimental  group  were  comparable  to  those  obtained  in  previous 
studies  (Huhman  et  al.,  1995;  Biello  and  Mrosovsky,  1996).  Neuropeptide  Y 
microinjections  at  CT  6  were  used  for  functional  assessment  (0.023nmol  in  400nl  saline, 
119  min  ±  11  [mean  ±  SEM],  n=19).  Further,  histological  placement  verification  is  set  so 
that  all  placements  lie  within  400µm  of  the  SCN  along  the  anterior-posterior,  dorsal- 
ventral  and  lateral  axes. 
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ti  ti  ''  výý Figure  12.  Phase  delays  to  light  were  significantly  attenuated  by  NPY  administration 
(Light+NPY;  p<0.05).  Microinjections  of  NPY  were  still  able  to  attenuate  phase  shifts  to 
light  in  the  presence  of  aY1  receptor  antagonist  (Light+Y  l  ant+NPY;  p<0.05).  However, 
the  administration  of  the  specific  Y5  receptor  antagonist  was  able  to  prevent  the 
attenuation  of  the  photic  phase  shift  by  NPY  (Light+Y5ant+NPY). 
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81 Figure  13.  Phase  advances  to  light  were  blocked  by  NPY  administration  (Light+NPY; 
p<0.05).  Microinjections  of  NPY  still  blocked  phase  shifts  to  light  in  the  presence  of  a  Yl 
receptor  antagonist  (Light+Y  l  ant+NPY;  p<0.05).  However,  administration  of  the  specific 
Y5  receptor  antagonist  was  not  only  able  to  prevent  the  attenuation  of  the  photic  shift  by 
NPY,  but  actually  potentiated  the  phase  shift  to  light  an  effect  also  observed  with  light  and 
the  antagonist  alone  (Light+Y5ant+NPY;  Light+Y5ant+Saline,  respectively). 
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Light+Ylant+Sal  Li  ght+YS+Sal  +ý Figure  14.  Representative  actograms  demonstrating  the  attenuation  of  light  induced  phase 
delays  at  CT  14  by  NPY  in  the  presence  of  either  a  Y1  or  Y5  receptor  antagonist.  Light 
exposure  for  15  minutes  (Light+Sal)  at  CT  14  resulted  in  phase  delays  of  the  free  running 
rhythm  in  Syrian  hamsters.  Microinjections  of  the  Y1  receptor  antagonist  prior  to  NPY 
administration,  during  light  exposure  (Light+Ylant+NPY),  did  not  affect  the  attenuating 
effects  of  NPY  at  this  time.  However,  the  presence  of  the  Y5  receptor  antagonist 
prevented  the  attenuation  of  the  photic  phase  shift  by  NPY  when  presented  during  the  light 
pulse  (Light+Y5ant+NPY).  Times  of  light  stimulation  are  indicated  by  inverted  open 
triangles. 
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85 Figure  15.  Representative  actograms  demonstrating  the  inhibition  of  light  induced  phase 
advances  at  CT  18  by  NPY  in  the  presence  of  either  a  Y1  or  Y5  receptor  antagonist.  Phase 
advances  to  light  were  blocked  by  the  administration  of  NPY  with  and  without  prior 
administration  of  the  Y1  receptor  antagonist  (Light+Ylant+NPY;  Light+Sal+NPY, 
respectively).  However,  microinjection  of  the  Y5  antagonist  during  light  exposure 
followed  by  either  saline  or  NPY  resulted  in  the  potentiation  of  the  photic  phase  shift 
(Light+Y5ant+Sal;  Light+Y5ant+NPY,  respectively).  Times  of  light  stimulation  are 
indicated  by  inverted  open  triangles. 
86 3.4  Discussion 
Microinjections  of  NPY,  in  vivo,  have  been  shown  to  attenuate  phase  delays  to  light  and 
inhibit  phase  advances  (Weber  and  Rea,  1997;  Lall  and  Biello,  2003b).  Furthermore,  a 
recent  study  reported  that  this  inhibitory  effect  of  NPY  on  photic  phase  shifts  was  mediated 
via  either  or  both  the  Y1  and/or  the  Y5  receptors  (Lall  and  Biello,  2003b).  Our  present 
study  has  shown  that  NPY  attenuates  photic  phase  delays  and  inhibits  light  induced  phase 
advances  via  the  Y5  receptor,  in  vivo.  Microinjection  of  the  Y5  receptor  antagonist 
prevented  NPY  from  influencing  the  phase  shifting  effects  of  light  during  the  early  and  late 
night.  Furthermore,  during  the  late  night  the  presence  of  the  Y5  antagonist  with  light 
stimulation  resulted  in  the  potentiation  of  the  phase  advancing  effects  of  light  at  this  time. 
A  similar  result  was  also  obtained  combining  NPY  with  light  and  the  Y5  receptor 
antagonist,  during  the  late  night.  Administration  of  the  Y1  receptor  antagonist  did  not 
influence  the  inhibitory  effects  of  NPY  on  both  advances  and  delays  to  light. 
The  administration  of  NMDA,  in  vivo  and  in  vitro,  onto  the  SCN  has  been  shown  to  mimic 
the  phase  shifting  effects  of  light  (Colwell  and  Menaker,  1992;  Ding  et  al.,  1994;  Shibata  et 
al.,  1994;  Mintz  et  al.,  1999).  A  recent  study  has  shown  that  NPY  applied  to  an  SCN  slice 
preparation  in  vitro  can  inhibit  the  phase  shifting  effects  of  NMDA  during  the  night 
(Yannielli  and  Harrington,  2001).  Further,  the  addition  of  a  Y5  receptor  antagonist 
blocked  the  effects  of  NPY  on  NMDA  induced  phase  shifts,  with  the  Y1  receptor 
antagonist  having  no  effect  on  the  interaction  between  NMDA  and  NPY  (Yannielli  and 
Harrington,  2001).  Our  study  is  the  first  to  report  that  the  interaction  between  light  and 
NPY  during  the  night  is  mediated  via  the  Y5  receptor  at  the  level  of  the  SCN,  in  vivo. 
Hence  further  clarifying  our  previous  findings  indicating  the  involvement  of  either  or  both 
the  Y1  and  the  Y5  receptors  (Lall  and  Biello,  2003b). 
97 At  present  there  are  at  least  six  known  subtypes  of  the  neuropeptide  Y  receptor 
(Ingenhoven  and  Beck-Sickinger,  1999).  These  receptors  have  been  pharmacologically 
defined  by  their  ability  to  bind  NPY,  PYY,  PP  and  synthetic  ligands  derived  from  these 
compounds.  The  Y2  receptor  can  be  defined  by  its  ability  to  bind  NPY3-36  (Grandt  et  al., 
1996),  however  [Leu  31,  Pro34]NPY  has  been  used  as  aY1  receptor  agonist  (Fuhlendorff  et 
al.,  1990),  but  also  binds  to  the  Y5  receptor  (Ingenhoven  and  Beck-Sickinger,  1999). 
Recently  a  new  Y5  receptor  antagonist  (RWJ5726,  used  in  this  study)  has  been  developed 
and  was  shown  to  bind  selectively  and  potently  to  the  Y5  receptor  subtype  (Youngman  et 
at.,  2000).  While  the  Y2  receptor  mediates  phase  shifts  to  NPY  during  the  mid  subjective 
day  (Golombek  et  al.,  1996;  Huhman  et  al.,  1996),  the  inhibitory  actions  of  NPY  on  photic 
phase  shifts  have  been  shown  to  involve  different  NPY  receptor  subtypes.  [Leu31, 
Pro34]NPY  microinjected  into  the  SCN  following  light  exposure  during  the  early  and  late 
night  attenuated  photic  shifts  in  the  circadian  pattern  of  wheel  running  behavior  in 
hamsters  (Lall  and  Biello,  2003b).  This  study  indicated  that  either  or  both  the  Y1  and  Y5 
receptors  were  involved  in  the  interaction  between  light  and  NPY  during  the  subjective 
night.  We  have  now  shown  that  the  Y5  receptor  is  responsible  for  the  inhibitory  effects  of 
NPY  on  photic  phase  shifts  and  not  the  Y1  receptor.  The  presence  of  the  Y5  receptor 
antagonist  prevented  the  ability  of  NPY  to  attenuate  both  light  induced  phase  advances  and 
delays,  however  administration  of  the  Y1  receptor  antagonist  had  no  effect  on  this 
interaction,  with  both  delays  and  advances  to  light  being  reduced  by  NPY  microinjection. 
Phase  shifts  to  light  during  the  late  night  were  potentiated  by  the  administration  of  the  Y5 
receptor  antagonist.  However,  phase  delays  to  light  were  unaffected  by  the  Y5  receptor 
antagonist  with  no  attenuation  or  potentiation  being  observed  with  treatments  administered 
at  this  time.  Previous  work  has  shown  that  the  administration  of  antiserum  raised  against 
88 NPY  also  potentiated  the  photic  phase  shift  during  the  late  night  (Biello,  1995). 
Neuropeptide  Y  levels  in  the  SCN  under  a  light-dark  cycle  have  been  shown  to  peak  at  the 
beginning  and  again  at  the  end  of  the  light  portion  of  the  photoperiod,  in  the  rat  (Shinohara 
et  at.,  1993).  In  the  same  study  it  was  found  that  NPY  levels  peaked  at  approximately  CT 
12  under  conditions  of  constant  darkness.  From  this  data  it  would  appear  that  in  the 
natural  environment  NPY  levels  peak  at  dawn  and  then  again  at  dusk.  It  is  likely  that  the 
peak  in  NPY  observed  at  dusk  is  the  result  of  an  endogenous  rhythm  of  NPY  as  opposed  to 
an  acute  response  to  the  light-dark  cycle  imposed  on  the  animals,  since  Shinohara  et  al, 
also  found  that  NPY  levels  tended  to  peak  at  times  during  the  transition  from  lights  off  to 
lights  on.  Therefore  it  is  possible  that  the  peak  observed  at  dawn  is  due  to  an  acute  action 
of  the  lights  coming  on. 
This  may  suggest  a  role  of  NPY  in  the  modulation  of  photic  phase  shifts,  given  the  present 
data  on  the  inhibitory  influences  of  NPY  on  photic  phase  shifts.  During  the  late  night, 
phase  shifts  to  light  may  be  regulated  by  NPY  release  acutely  induced  by  lights  on. 
Therefore  the  presence  of  the  antagonist  would  prevent  the  modulation  of  the  photic 
stimulus  by  NPY  resulting  in  a  potentiation  of  the  phase  shifting  effects  of  light  during  the 
late  night.  However,  during  the  early  night  NPY  levels  are  endogenously  high,  hence  SCN 
cells  are  under  the  influence  of  NPY  before  the  light  pulse.  Therefore  the  Y5  antagonist 
microinjected  at  CT  14  may  not  be  able  to  prevent  the  actions  of  the  previously  released 
NPY  at  CT  12.  Thereby  limiting  the  light  induced  phase  shift  at  this  time.  Furthermore, 
phase  shifts  to  light  in  the  hamster  appear  to  be  larger  during  the  late  subjective  night  than 
during  the  early  subjective  night.  This  may  be  a  result  of  the  endogenous  rhythm  of  NPY 
within  the  SCN.  Our  study  may  also  indicate  a  possible  role  for  the  NPY  peak  observed  at 
89 dawn  under  a  light-dark  cycle.  This  peak  may  act  to  modulate  the  photic  pulse  received 
during  the  advance  portion  when  lights  come  on  during  the  beginning  of  the  light-dark 
cycle.  Hence  preventing  the  clock  from  falling  out  of  synchronization  with  the 
photoperiod. 
The  neurotransmitter  y-amino  butyric  acid  (GABA)  is  found  in  the  majority  of  SCN 
neurons  as  well  as  in  many  SCN  afferents  (Decavel  and  Van  den  Pol,  1990;  Moore  and 
Speh,  1993).  Furthermore,  NPY  and  GABA  are  co-localized  in  synaptic  terminals  within 
the  SCN  (Francois-Bellan  et  at.,  1990).  The  GABAergic  system  has  been  implicated  in  the 
phase  advancing  properties  of  NPY  during  the  middle  of  the  subjective  day  as  phase  shifts 
to  NPY  were  blocked  by  the  administration  of  the  GABAA  receptor  antagonist  bicuculline 
(Huhman  et  al.,  1995).  Also,  the  GABAA  receptor  agonist,  muscimol,  was  shown  to  block 
both  phase  advances  and  delays  to  light  (Gillespie  et  al.,  1996;  Gillespie  et  al.,  1997). 
However,  during  the  early  and  late  night  the  presence  of  bicuculline  did  not  influence  the 
ability  of  NPY  to  inhibit  photic  phase  shifts  (Lall  and  Biello,  2003a).  Bicuculline 
administration  with  light  alone  during  the  early  night  resulted  in  the  potentiation  of  the 
photic  phase  shift,  in  vivo  (Gillespie  et  al.,  1996;  Lall  and  Biello,  2003a),  while  light 
induced  phase  advances  were  unaffected  by  bicuculline  microinjections  (Lall  and  Biello, 
2003a)  [See  Chapter  4].  It  is  possible  that  phase  delays  to  light  are  under  GABAergic 
regulation  as  well  as  NPY,  but  phase  advances  primarily  rely  on  the  acute  effects  of  NPY 
on  photic  shifts  at  this  time.  Therefore,  during  the  early  subjective  night  phase  delays  to 
light  are  modulated  by  NPY  and  GABA,  hence  blocking  NPY  regulation  via  the  Y5 
receptor  does  not  influence  the  photic  phase  shift,  as  the  GABAergic  tone  is  unaffected. 
Furthermore,  bicuculline  administration  potentiates  phase  delays  to  light,  adding  further 
90 support  to  the  involvement  of  GABA  in  the  modulation  of  photic  shifts  at  this  time. 
During  the  late  night  GABAergic  tone  may  be  much  less  than  it  is  during  the  early  night, 
hence  the  observed  potentiation  in  photic  phase  shifts  with  the  Y5  receptor  antagonist  and 
light  stimulation.  Taken  together  it  is  possible  that  NPY  plays  a  greater  role  in  the 
regulation  of  light  induced  phase  advances. 
The  current  study  has  shown  the  involvement  of  the  Y5  receptor  subtype  in  the  interaction 
between  NPY  and  light  during  the  early  and  late  subjective  night.  Furthermore,  it  gives 
and  insight  into  the  possible  non-photic  mechanisms  that  may  act  on  the  SCN  to  provide 
synchronization  to  the  natural  environment. 
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Neuropeptide  Y,  GABA  and circadian  phase  shifts  to  photic  stimuli 
Having  established  that  NPY  utilizes  the  NPY  Y5  receptor  subtype  in  its  interaction  with 
light,  the  next  set  of  experiments  were  designed  to  investigate  the  possible  neural 
mechanisms  induced  by  NPY  in  its  inhibitory  actions  on  photic  phase  shifts 
A  possible  pathway  for  the  non-photic  resetting  of  the  clock  is  thought  to  originate  from 
the  IGL,  which  conveys  information  to  the  SCN  through  the  geniculohypothalamic  tract 
and  utilizes  among  others  neuropeptide  Y  (NPY)  and  -y-aminobutyric  acid  (GABA)  as 
neurotransmitters.  Phase  advances  to  NPY  during  the  mid  subjective  day  have  been  shown 
to  utilize  a  GABAergic  mechanism,  as  the  administration  of  bicuculline,  a  GABAA 
receptor  antagonist,  blocked  NPY  phase  shifts. 
Photic  and  non-photic  stimuli  have  been  shown  to  interact  during  the  early  and  late 
subjective  night.  Microinjections  of  NPY  or  muscimol,  a  GABAA  receptor  agonist,  into 
the  region  of  the  SCN  can  attenuate  light  induced  phase  shifts  during  the  early  and  late 
subjective  night.  The  precise  mechanism  for  these  interactions  is  unknown. 
In  the  current  study  we  investigate  if  a  GABAergic  mechanism  is  involved  in  the 
interaction  between  NPY  and  light  during  the  early  and  late  subjective  night. 
Microinjections  of  NPY  significantly  attenuated  light  induced  phase  delays  and  inhibited 
phase  advances  (p<0.05).  The  administration  of  bicuculline  during  light  exposure,  before 
92 NPY  microinjection  did  not  alter  the  ability  of  NPY  to  attenuate  light  induced  phase  delays 
and  block  photic  phase  advances. 
These  results  indicate  that  NPY  attenuates  photic  phase  shifts  via  a  mechanism 
independent  of  GABAA  receptor  activation.  Furthermore  it  is  evident  that  NPY  influences 
circadian  clock  function  via  differing  cellular  pathways  over  the  course  of  a  circadian 
cycle. 
93 4.1  Introduction 
The  neurotransmitter  y-aminobutyric  acid  (GABA)  is  found  in  the  majority  of  SCN 
neurones  as  well  as  in  many  SCN  afferents  (Decavel  and  Van  den  Pol,  1990;  Moore  and 
Speh,  1993).  Furthermore,  NPY  and  GABA  have  been  co-localized  in  synaptic  terminals 
within  the  SCN  (Francois-Bellan  et  al.,  1990).  The  GABAergic  system  has  been 
implicated  in  the  phase  advancing  property  of  NPY  during  the  middle  of  the  subjective 
day.  Phase  shifts  to  NPY  were  blocked  by  the  administration  of  the  GABAA  receptor 
antagonist,  bicuculline  (Huhman  et  al.,  1995).  The  blockade  of  sodium  dependent  action 
potentials  by  tetrotoxin  blocked  NPY,  but  not  muscimol,  a  GABAA  receptor  agonist, 
induced  phase  advances  (Huhman  et  al.,  1997).  These  findings  suggest  that  NPY  utilises  a 
GABAergic  mechanism  to  phase  advance  the  circadian  rhythm  in  mammals  during  the 
subjective  day. 
GABAA  active  drugs  microinjected  into  the  SCN  during  the  subjective  night  have  also 
been  shown  to  modulate  photic  phase  shifts,  in  a  manner  similar  to  NPY.  Muscimol 
administration  attenuated  both  light  induced  phase  advances  and  delays  (Gillespie  et  al., 
1996;  Gillespie  et  al.,  1997).  Furthermore,  bicuculline  microinjections  potentiated  photic 
phase  shifts  during  the  early  subjective  night  (Gillespie  et  al.,  1996),  a  result  similar  to  that 
observed  with  the  administration  of  antiserum  raised  against  NPY  prior  to  a  light  pulse 
given  during  the  late  subjective  night  (Biello,  1995).  However,  in  vitro  data  shows  that 
NPY  is  able  to  influence  SCN  cells  directly  and  independently  of  a  GABAergic 
mechanism  (Cutler  et  al.,  1998). 
94 Thus,  it  is  possible  that  NPY  utilises  a  GABAergic  pathway  in  influencing  photic  phase 
shifts  during  the  early  and  late  subjective  night.  The  purpose  of  the  present  study  was  to 
determine  whether  NPY  mediates  its  modulatory  effect  on  photic  phase  shifts  via  a 
GABAergic  mechanism. 
95 4.2  Experimental  procedures 
4.2.1  Subjects 
Experimental  procedures  were  carried  out  under  licence  by  the  Home  Office  (UK)  in 
accordance  with  the  Animals  Scientific  Procedures  Act  (1986).  Adult  male  Syrian 
hamsters  (40  days  old,  Harlan  Sprague-Dawley,  Oxon,  UK)  were  housed  individually  in 
plastic  cages  fitted  with  16  cm  running  wheels  connected  to  a  computer  that  summed 
wheel  revolutions  in  10  minute  activity  bins  (Dataquest  Pro-Data  software,  Data  Sciences 
Inc.,  Roseville,  MN,  USA).  Food  and  water  were  available  ad  libitum.  Animals  (n=21) 
were  maintained  under  a  LD  cycle  of  14  hours  light  and  10  hours  of  darkness  and  then 
transferred  to  constant  conditions  (22  ±  2°C;  14-18  lux  dim  red  light)  10  days  before 
treatment.  Animals  were  re-entrained  by  this  method  following  a  maximum  of  three 
treatments  before  continuing  with  further  experimental  conditions.  All  efforts  were  made 
to  minimise  the  number  of  animals  used  and  their  suffering. 
4.2.2  Surgery  and  Injections 
See  appendix  I  for  a  detailed  description  of  the  surgical  procedure. 
Hamsters  were  anaesthetised  with  halothane  gas  throughout  the  length  of  the  surgery. 
Animals  received  cannula  guides,  which  were  implanted  to  a  depth  of  5.6mm  below  the 
skull  surface  at  a  10°  angle  and  fixed  to  the  skull  with  fine  machine  screws  and  dental 
cement.  Cannula  guides  were  stereotaxically  aimed  at  the  SCN  (co-ordinates  relative  to 
bregma:  AP+0.4mm,  ML  1.0mm,  upper  incisor  bar  -2  mm).  After  recovery  from  surgery 
(1  week  under  LD  14:  1Oh),  animals  were  transferred  into  cages  fitted  with  running  wheels 
and  maintained  for  7-10  days  under  LD  14:  1Oh  before  being  placed  into  constant 
conditions.  In  all  treatments  the  vehicle  consisted  of  a  0.9%  saline  solution.  Porcine  NPY 
96 (0.023nmol  in  200nl  saline,  Calbiochem,  UK)  and  bicuculline  methobromide,  a 
competetive  GABAA  antagonist  (0.18nmol  in  200n1  saline,  Sigma,  UK)  were  administered 
using  a  28  gauge  infusion  cannula  attached  to  a1  µl  Hamilton  syringe.  The  infusion 
cannula  extended  2.4  mm  from  the  base  of  the  guide  cannula. 
4.2.3  Experimental  treatments 
Prior  to  the  start  of  the  experiment  all  animals  were  injected  with  NPY  at  CT  6  five  days 
after  being  placed  into  constant  conditions.  These  microinjections  were  used  as  functional 
assessments  to  verify  cannula  placements. 
Experiment  I  (n=12).  Hamsters  completed  the  following  sequence  of  treatments:  (1)  a  15 
minute  light  pulse  (130  lux)  at  CT14  directly  followed  by  vehicle  administration,  (2)  a  15 
minute  light  pulse  at  CT14  with  bicuculline  administration  at  CT14.08  and  saline 
administration  at  CT  14.17,  (3)  a  15  minute  light  pulse  at  CT14  with  saline  administration 
at  CT14.08  and  NPY  administration  at  CT14.17,  (4)  a  15  minute  light  pulse  at  CT14  with 
bicuculline  administration  at  CT14.08  and  NPY  administration  at  CT14.17,  (5)  bicuculline 
administration  at  CT14  followed  by  saline  administration  at  CT14.08,  (6)  saline 
administration  at  CT14  followed  by  NPY  administration  at  CT14.08. 
Experiment  2  (n=9).  Hamsters  completed  the  following  sequence  of  treatments:  (1)  a  15 
minute  light  pulse  (130  lux)  at  CT18  directly  followed  by  vehicle  administration,  (2)  a  15 
minute  light  pulse  at  CT18  with  bicuculline  administration  at  CT18.08  and  saline 
administration  at  CT18.17,  (3)  a  15  minute  light  pulse  at  CT18  with  saline  administration 
at  CT18.08  and  NPY  administration  at  CT18.17,  (4)  a  15  minute  light  pulse  at  CT18  with 
97 bicuculline  administration  at  CT  18.08  and  NPY  administration  at  CT  18.17,  (5)  bicuculline 
administration  at  CT  18  followed  by  saline  administration  at  CT  18.08,  (6)  saline 
administration  at  CT18  followed  by  NPY  administration  at  CT18.08. 
4.2.4  Data  analysis 
For  activity  onset  calculation  see  appendix  III. 
Data  from  each  set  of  treatments  was  analysed  by  the  one-way  repeated  measures 
ANOVA,  followed  by  Bonferroni's  method  for  multiple  comparisons.  All  t-values 
reported  were  derived  from  multiple  comparison  tests. 
4.2.5  Cannula  Placement 
See  appendix  IV  for  cannula  placement  assessment  methods. 
98 4.3  Results 
4.3.1  Effects  of  bicuculline  on  the  attenuation  of  photic  phase  delays  by  NPY. 
The  administration  of  bicuculline  during  light  exposure  and  preceding  NPY  microinjection 
did  not  significantly  alter  the  ability  of  NPY  to  attenuate  the  photic  phase  shift  with  shifts 
of  -14  ±  13  minutes  (mean  ±  SEM)  in  the  presence  of  bicuculline  and  -18  ±8  minutes 
with  a  vehicle  substitution  of  bicuculline  (t  =0.34,  p>0.05)  (Fig.  16).  However, 
microinjections  of  bicuculline  following  light  and  preceding  saline  administration  resulted 
in  phase  shifts  significantly  greater  than  those  of  light  with  saline  alone  resulting  in  shifts 
of-96  ±4  minutes  and  -61  ±5  minutes  respectively  (t  =3.38,  p<0.05). 
NPY  administration  following  light  exposure  resulted  in  the  attenuation  of  the  photic  phase 
shift  observed  with  light  and  saline  alone  with  average  shifts  of  -18  ±8  minutes  and  -61  ± 
5  minutes  respectively  (t  =4.19,  p<0.05).  Microinjections  of  NPY  followed  by  saline,  or 
bicuculline  followed  by  saline,  resulted  in  phase  shifts  not  significantly  different  from  each 
other  (-19  ±7  minutes  and  -5  ±4  minutes  respectively,  t  =1.31,  p>0.05),  but  both  were 
significantly  different  from  shifts  resulting  from  light  followed  by  saline  alone  (F(5,66)= 
23.6,  p<0.01)  (Fig.  18). 
99 4.3.2  Effects  of  bicuculline  on  the  inhibition  of  photic  phase  advances  by  NPY. 
The  administration  of  bicuculline  following  light  exposure  and  preceding  NPY 
microinjection  did  not  significantly  alter  the  ability  of  NPY  to  block  photic  phase 
advances,  with  resulting  phase  shifts  of  -6  ±5  minutes  relative  to  those  observed  with 
light,  saline  and  NPY  treatments  (7  ±  15  minutes,  x0.85,  p>0.05)  (Fig.  17). 
Microinjections  of  bicuculline  and  saline  following  light  exposure  were  not  significantly 
different  from  treatments  with  saline  following  photic  stimulation  during  the  subjective 
late  night,  with  photic  phase  shifts  of  98  ±5  minutes  and  106  ±4  minutes  respectively 
(F(s,  47)=23.1,  p<0.01).  The  administration  of  bicuculline  followed  by  saline,  and  NPY 
followed  by  saline,  were  not  significantly  different  from  each  other  with  average  shifts  of 
22  ±  10  minutes  and  7±  15  minutes  respectively  (t=0.9,  p>0.05)  (Fig.  19). 
4.3.3  Cannula  placement  verification 
Neuropeptide  Y  microinjections  at  CT  6  were  used  for  functional  assessment  (0.047nmol 
in  200n1  saline,  123  min  ±8  [mean  ±  SEM],  n=21).  All  phase  shifts  seen  in  this 
experimental  group  were  comparable  to  those  obtained  in  previous  studies  (Hufiman  et  at., 
1995;  Biello  and  Mrosovsky,  1996).  Further,  histological  placement  verification 
confirmed  that  cannula  were  within  400µm  of  the  SCN  along  the  anterior-posterior,  dorsal- 
ventral  and  lateral  axes. 
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101 Figure  16.  Phase  delays  to  light  were  significantly  attenuated  following  NPY 
administration  (p<0.05).  Microinjection  of  bicuculline  during  light  exposure  followed  by 
NPY  administration  also  resulted  in  a  significant  attenuation  of  the  photic  shift  (p<0.05). 
However,  bicuculline  administration  during  the  pulse  of  light  followed  by  saline 
microinjection  resulted  in  a  significant  potentiation  of  the  light  induced  phase  shift  at  this 
time  (p<0.05;  n=12). 
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103 Figure  17.  Phase  advances  to  light  were  significantly  attenuated  following  NPY 
administration  (p<0.05).  Microinjection  of  bicuculline  during  light  exposure  followed  by 
NPY  administration  also  resulted  in  a  significant  attenuation  of  the  photic  shift  (p<0.05). 
However,  the  administration  of  bicuculline  during  the  pulse  of  light  followed  by  saline 
microinjection  did  not  alter  the  phase  shifting  properties  of  light  at  this  time  (p>0.05;  n=9). 
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105 Figure  18.  Representative  actograms  demonstrating  the  attenuation  of  light  induced  phase 
delays  at  CT  14  by  NPY  in  the  presence  of  bicuculline.  Light  exposure  for  15  minutes  at 
CT  14  resulted  in  phase  delays  of  the  free  running  rhythm  in  Syrian  hamsters.  However 
microinjections  of  bicuculline  prior  to  NPY  administration,  during  light  exposure,  did  not 
affect  the  attenuating  effects  of  NPY  at  this  time.  Times  of  light  stimulation  are  indicated 
by  inverted  open  triangles. 
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107 Figure  19.  Representative  actograms  demonstrating  the  inhibition  of  light  induced  phase 
advances  at  CT  18  by  NPY  in  the  presence  of  bicuculline.  Phase  advances  to  light  were 
blocked  by  the  administration  of  NPY  with  and  without  prior  administration  of  bicuculline. 
Times  of  light  stimulation  are  indicated  by  inverted  open  triangles. 
108 4.4  Discussion 
Neuropeptide  Y  has  been  previously  shown  to  attenuate  phase  delays  to  light  and  inhibit 
phase  advances,  in  vivo  (Weber  and  Rea,  1997;  Lall  and  Biello,  2002).  Microinjections  of 
the  GABAA  antagonist,  bicuculline,  did  not  alter  the  inhibitory  effects  of  NPY  on  photic 
phase  shifts  during  the  subjective  night.  Phase  advances  to  NPY  during  the  subjective  day 
were  shown  to  be  blocked  by  the  administration  of  bicuculline,  (Huhman  et  al.,  1995), 
suggesting  that  NPY  phase  shifts  were  mediated  via  a  GABAergic  mechanism.  In  the 
present  study  we  have  shown  it  is  likely  that  NPY  does  not  influence  photic  phase  shifts 
via  a  mechanism  involving  the  GABAA  receptor  subtype.  This  further  strengthens 
previous  evidence  suggesting  that  the  interaction  site  of  NPY  and  light  lies  downstream 
from  receptor  binding  sites  within  SCN  cells.  Phase  shifts  to  light,  presented  in  vivo, 
during  the  early  subjective  night  were  also  blocked  by  the  application  of  NPY  in  vitro  up  to 
30  minutes  post  light  exposure  (Yannielli  and  Harrington,  2000).  Together  this  evidence 
indicates  the  postsynaptic  effects  of  NPY  on  photic  phase  shifting. 
Microinjections  of  muscimol,  a  GABAA  receptor  agonist,  have  been  shown  to  inhibit  both 
phase  delays  and  advances  to  light  (Gillespie  et  al.,  1996;  Gillespie  et  al.,  1997). 
Neuropeptide  Y  microinjections  attenuated  phase  delays  to  light  and  inhibited  phase 
advances  (Lall  and  Biello,  2003b).  Photic  information  is  thought  to  be  conveyed  to  the  SCN 
via  a  monosynaptic  pathway  utilizing  glutamate  as  its  principal  neurotransmitter  (Ebling, 
1996).  Light  and  glutamate  phase  shift  the  SCN  mostly  via  NMDA  receptors  during  the 
subjective  night  (de  Vries  et  al.,  1994;  Mintz  et  al.,  1999).  GABAA  receptors  conduct 
mostly  chloride  ions  (Sivilotti  and  Nistri,  1991;  Kaila,  1994).  The  conductance  of  these 
chloride  ions  through  the  GABAA  receptor  has  been  shown  to  rise  quickly  inducing  a  rapid 
109 hyperpolarizing  effect  on  cells  (Mierlak  and  Farb,  1988;  Tauck  et  al.,  1988).  Taken 
together,  it  is  possible  that  the  activation  of  GABAA  receptors  by  muscimol  inhibits  both 
photic  phase  delays  and  advances  via  a  mechanism  involving  changes  in  membrane 
conductance.  However,  NPY  appears  not  to  influence  SCN  cells  at  the  cell  surface,  but  at 
the  level  of  protein  synthesis  (Hall  et  al.,  1999;  Maywood  et  al.,  2002). 
In  agreement  with  a  previous  study  (Gillespie  et  al.,  1996)  we  found  microinjections  of 
bicuculline  during  the  early  subjective  night  potentiated  the  phase  shifting  effects  of  light 
at  this  time.  Phase  delays  to  light  were  increased  by  approximately  57%  following 
bicuculline  administration.  However,  this  effect  of  bicuculline  did  not  alter  the  ability  of 
NPY  to  attenuate  photic  phase  shifts  when  light,  bicuculline  and  NPY  were  administered  in 
sequence.  During  the  early  subjective  night  NPY  levels  have  been  shown  to  peak  in 
nocturnal  rodents,  possibly  because  of  increased  activity  levels  at  this  time  (Shinohara  et 
al.,  1993).  Due  to  the  co-localization  of  NPY  and  GABA  within  the  same  synaptic 
terminals  (Francoisbellan  et  al.,  1990)  it  is  possible  that  GABA  levels  also  rise.  This 
increase  in  GABA  will  result  in  a  baseline  activation  of  GABAA  receptors  thereby 
generating  a  natural  chloride  conductance  within  SCN  cells  at  this  time.  Hence  the 
application  of  bicuculline  could  block  this  underlying  chloride  conductance  and  remove 
the  hyperpolarizing  effects  of  GABA  resulting  in  potentiated  phase  shifts  to  light  during 
the  early  night.  During  the  late  subjective  night  activity  levels  tend  to  be  low,  therefore  it 
is  possible  that  the  underlying  chloride  conductance  within  SCN  cells  is  also  reduced. 
Hence  phase  advances  to  light  maybe  under  little  or  no  influence  of  GABAA  receptor 
activation. 
110 Bicuculline  did  not  alter  the  attenuating  effect  of  NPY  on  light  induced  phase  delays.  It 
may  have  been  expected  that  if  bicuculline  increases  phase  delays  to  light,  that  NPY's 
ability  to  influence  this  shift  would  be  substantially  impaired.  However  this  was  not  the 
case.  Furthermore,  bicuculline  microinjections  during  the  late  subjective  night  following 
light  exposure  did  not  significantly  alter  the  resulting  phase  shift  in  comparison  to  light 
administration  alone.  Taken  together  this  result  may  indicate  that  the  interaction  between 
GABA  and  light  lies  at  the  level  of  receptor  activation  on  SCN  cells,  during  the  early  and 
late  night.  Further,  the  interaction  between  NPY  and  light  probably  lies  at  a  level  post 
receptor  activation  within  SCN  cells,  possibly  at  the  level  of  gene  expression. 
Light  stimulation  results  in  the  increase  of  Per  mRNA  (mPer)  levels,  in  mice  (Shearman  et 
al.,  1997;  Zylka  et  al.,  1998).  Neuropeptide  Y  administration  has  been  shown  to  reduce 
mPer  levels  in  hamsters  and  mice  (Fukuhara  et  al.,  2001;  Maywood  et  al.,  2002).  The 
resulting  potentiation  of  the  light  induced  phase  shift  following  bicuculline  microinjection, 
during  the  early  subjective  night,  may  possibly  act  to  increase  the  quantity  of  mPer 
expressed,  thereby  resulting  in  a  shift  of  greater  magnitude  than  that  observed  with  light 
alone  at  this  time.  However,  NPY  administration  following  light  and  bicuculline 
microinjections  was  still  able  to  attenuate  the  photic  phase  shift.  This  would  indicate  that 
NPY's  ability  to  reduce  the  increase  in  mPer  expression  was  not  impaired  by  the  presence 
of  bicuculline.  Taken  together  it  is  possible  that  bicuculline  administration  following  light 
exposure  during  the  early  subjective  night  may  increase  the  quantity  of  mPer,  but  does  not 
increase  the  rate  of  synthesis,  hence  NPY  is  still  able  to  inhibit  mPer  production  long 
before  the  cytosolic  concentrations  of  mPer  start  to  rise  above  those  expected  with  light 
111 alone.  The  complex  interaction  between  NPY  and  light  may  lie  at  the  molecular  level,  and 
this  should  provide  an  area  for  future  investigation. 
It  is  clear  that  both  GABA  and  NPY  provide  a  modulatory  role  in  the  mediation  of  photic 
phase  shifts  observed  in  mammals.  Both  these  non-photic  stimuli  interact  at  different  sites 
within  the  circadian  system  to  influence  light  induced  phase  shifts,  but  from  this  study  it  is 
evident  that  each  stimuli  interacts  with  light  independently.  Such  a  mechanism  may  be 
advantageous  in  the  evolution  and  adaptation  of  mammals  to  our  ever-changing 
environment. 
112 Chapter  5 
Attenuation  of  phase  shifts  to  light  by  activity  or  neuropeptide  Y:  a  time 
course  study. 
Previous  work  has  shown  that  NPY  can  modulate  both  light  induced  phase  advances  and 
delays.  Furthermore,  NPY  binds  to  the  Y5  receptor  in  this  interaction.  Also,  it  appears 
that  NPY  does  not  utilize  a  GABAA  dependent  pathway  to  mediate  its  effects  on  photic 
phase  shifts.  Taken  together  evidence  would  suggest  that  the  interaction  between  NPY  and 
light  occurs  down  stream  from  Y5  receptor  binding  sites,  probably  within  SCN  cells. 
The  next  sets  of  experiments  were  designed  to  use  a  functional  in  vivo  method  to  try  and 
locate  the  possible  site  of  interaction  between  NPY  and  light.  In  these  studies  I  have  also 
used  the  novel  wheel  stimulus  and  aim  to  see  if  this  behavioural  cue  alters  phase  shifts  to 
light  in  a  similar  manner  to  NPY  microinjections.  The  novel  wheel  allows  us  to  observe 
the  effects  of  naturally  stimulating  NPY  release  rater  than  gross  administration  via  cannula 
application.  Furthermore,  it  also  allows  the  correlation  between  the  two  types  of 
experimental  methods. 
Interactions  between  photic  and  behavioural  stimuli  were  investigated  during  the  late 
subjective  night,  six  hours  after  activity  onset  in  Syrian  hamsters  (CT18).  Light  pulses  of 
130  lux  for  15  minutes  at  this  time  resulted  in  phase  advance  shifts.  Novel  wheel 
exposure,  for  a  period  of  3  hours,  following  photic  stimulation  was  able  to  attenuate  the 
phase  advancing  effects  of  light.  A  time  delay  of  up  to  60  minutes  between  photic  and 
behavioural  stimuli  also  resulted  in  significant  attenuation  of  light  induced  phase  shifts 
113 (p<0.05).  A  90  minute  interval  between  stimuli  resulted  in  no  significant  attenuation. 
Novel  wheel  exposure  mediates  its  effects  via  the  intergeniculate  leaflet,  which  conveys 
information  to  the  SCN  and  utilises  neuropeptide  Y  (NPY)  as  its  primary  neurotransmitter. 
Phase  shifts  to  light  pulses  given  at  CT18  were  attenuated  by  NPY  administration. 
Neuropeptide  Y  injections  up  to  60  minutes  post  light  exposure  significantly  attenuated 
phase  shifts  by  50%  on  average.  However  a  90  minute  interval  between  light  and  NPY 
microinjection  did  not  significantly  affect  light  induced  phase  shifts. 
These  results  confirm  previous  work  indicating  that  novel  wheel  exposure  and  NPY 
administration  can  modulate  light  induced  phase  shifts  during  the  late  night.  Further,  they 
show  for  the  first  time  that  the  time  course  for  this  interaction  is  similar  between  wheel 
running  and  NPY.  Also,  most  significantly  these  results  indicate  that  the  interaction 
between  NPY  or  novel  wheel  exposure  and  light  probably  occurs  downstream  from 
receptor  binding  sites  within  SCN  cells. 
114 5.1.  Introduction 
Non-photic  stimuli  affect  the  phase  resetting  property  of  light.  Timed  bouts  of  wheel 
running  have  been  shown  to  attenuate  the  phase  shifting  effects  of  photic  stimuli  (Ralph 
and  Mrosovsky,  1992;  Mistiberger  and  Antle,  1998).  Light  can  also  attenuate  the  phase 
resetting  effects  of  activity  during  the  mid-subjective  day  (the  rest  phase  in  nocturnal 
rodents)  (Mrosovsky,  1991).  These  interactions  provide  evidence  for  a  complex  series  of 
neural  pathways  that  provide  input  onto  the  circadian  pacemaker,  the  suprachiasmatic 
nucleus  in  mammals,  and  ultimately  influencing  biological  and  behavioural  output. 
Phase  shifts  to  light  during  the  subjective  night  (the  active  phase  in  nocturnal  rodents)  can 
be  attenuated  by  NPY  or  serotonin  agonists  (Rea  et  al.,  1994)  or  potentiated  by  antiserum 
to  NPY  (Biello,  1995).  Phase  shifts  to  glutamate,  in  vitro,  can  be  blocked  by  the 
administration  of  NPY  (Biello  et  al.,  1997a).  Current  evidence  has  shown  NPY  to  be 
involved  in  the  ability  of  non-photic  stimuli  to  attenuate  light  induced  phase  shifts,  in  vivo. 
NPY  injections  directly  onto  the  SCN  were  shown  to  attenuate  the  phase  shifting  effects  of 
light  during  the  late  subjective  night  (Weber  and  Rea,  1997). 
The  recent  development  of  an  in  vivo-  in  vitro  experimental  design  by  Yannielli  and 
Harrington  has  provided  further  evidence  for  the  interaction  of  NPY  and  photic  stimuli. 
Light  pulses  were  presented  to  animals  in  vivo  followed  by  NPY  administration  to  the  SCN 
in  a  slice  preparation,  in  vitro.  NPY  was  able  to  attenuate  the  phase  shifting  effects  of  light 
up  to  thirty  minutes  post  light  exposure  during  the  early  subjective  night  (Yannielli  and 
Harrington,  2000).  The  fact  that  NPY  administered  in  vitro  can  attenuate  light  induced 
115 phase  shifts  up  to  30  minutes  post  light  pulse  suggests  that  NPY  influences  mechanisms 
downstream  from  receptor  binding  sites  on  SCN  cells. 
It  is  possible  that  the  modulation  of  light  induced  phase  shifts  is  a  mechanism  for  the 
control  and  maintenance  of  a  circadian  rhythm.  Experiments  were  designed  to  test  the 
ability  of  non-photic  stimuli,  novel  wheel  running  and  NPY,  in  the  regulation  of  photic 
phase  shifts. 
116 5.2.  Experimental  procedures 
5.2.1.  Subjects 
Adult  male  Syrian  hamsters  (40  days  old,  Harlan  Sprague-Dawley,  Oxon,  UK)  were 
housed  individually  in  plastic  cages  fitted  with  16  cm  running  wheels  connected  to  a 
computer  that  summed  wheel  revolutions  in  10  minute  activity  bins  (Dataquest  Pro-Data 
software,  Data  Sciences  Inc.,  Roseville,  MN,  USA).  Food  and  water  were  available  ad 
libitum.  Animals  were  maintained  under  a  LD  cycle  of  14  hours  light  and  10  hours  of 
darkness  and  then  transferred  to  constant  conditions  (22  ±  2°C;  14-18  lux  dim  red  light)  10 
days  before  treatment.  Group  la  (n=10)  and  group  lb  (n=10)  animals  were  treated  with 
behavioural  stimuli  only.  Group  2a  (n=12)  and  group  2b  (n=12)  animals  were  treated  with 
behavioural  stimuli  as  well  as  intraventricular  administration  of  NPY. 
5.2.2.  Surgery  and  injections 
See  appendix  I  for  a  detailed  description  of  the  surgical  procedure. 
Hamsters  in  group  2  were  anaesthetised  with  halothane  gas  throughout  the  length  of  the 
surgery.  Animals  received  cannula  guides,  which  were  implanted  to  a  depth  of  5.1mm 
below  the  skull  surface  and  fixed  to  the  skull  with  fine  machine  screws  and  dental  cement. 
Cannula  guides  were  stereotaxically  aimed  at  the  third  ventricle,  just  above  the  SCN  (co- 
ordinates  relative  to  bregma:  AP+0.6mm,  ML  0.1  mm,  upper  incisor  bar  -2  mm).  After 
recovery  from  surgery  (1  week  under  LD  14:  10h),  animals  were  transferred  into  cages 
fitted  with  running  wheels  and  maintained  for  7-10  days  under  LD  14:  1Oh  before  being 
placed  into  constant  conditions.  Porcine  NPY  (Calbiochem,  UK)  was  administered  using  a 
28  gauge  infusion  cannula  attached  to  a1  µl  Hamilton  syringe  at  a  concentration  of  Ing/nl 
117 at  a  volume  of  200n1.  The  infusion  cannula  extended  2.4  mm  from  the  base  of  the  guide 
cannula. 
NPY  was  dissolved  in  artificial  cerebral  spinal  fluid  (ACSF;  in  mM;  NaCl  124,  KC133, 
KH2PO4  1.2,  CaC12  2.5,  MgSO4  1,  NaHCO3  2.5,  glucose  10).  The  vehicle  consisted  of 
ACSF  only. 
5.2.3.  Experimental  treatments 
Hamsters  in  group  la  completed  the  following  sequence  of  treatments:  (1)  a3  hour  bout  of 
wheel  running  induced  by  confinement  to  a  novel  running  wheel  at  circadian  time  18 
(CT18;  six  hours  after  activity  onset),  (2)  a  15  minute  light  pulse  (130  lux)  at  CT18,  (3)  a 
15  minute  light  pulse  at  CT18  with  exposure  to  a  novel  running  wheel  at  one  of  the 
following  CT  times:  18.25,18.5,18.75,19.25,19.75.  Additional  control  animals  (group 
lb)  received  a3  hour  period  of  novel  wheel  exposure  at  the  following  circadian  times: 
18.5,19.19.5,20. 
Hamsters  in  group  2a  completed  the  following  treatments  (1)  a  light  pulse  at  CT18,  (2) 
NPY  administration  at  CT  18,  (3)  a  light  pulse  at  CT18  in  combination  with  NPY 
administration  at  one  of  the  following  CT  times:  18.25,18.5,18.75,19.25,19.75,  (4) 
administration  of  the  vehicle  at  CT  18,  (5)  a  15  minute  light  pulse  at  CT  18  directly 
followed  by  vehicle  administration.  Additional  control  animals  (group  2b)  received  NPY 
microinjections  at  the  following  circadian  times:  18.5,19.19.5,20. 
5.2.4.  Data  analysis 
For  activity  onset  calculation  see  appendix  III. 
118 Data  from  each  set  of  treatments  was  analysed  by  the  one-way  ANOVA,  followed  by 
Bonferroni's  method  for  multiple  comparisons. 
5.2.5.  Cannula  placement  verification 
See  appendix  IV  for  cannula  placement  assessment  methods. 
119 5.3.  Results 
5.3.1.  Phase  shifts  to  light  and  activity  at  CT  18 
Photic  stimulation  alone  resulted  in  phase  advances  of  124  ±8  minutes  (mean  ±  SEM). 
Wheel  running  induced  by  confinement  to  a  novel  wheel  at  CT  18  resulted  in  a  phase 
change  of  -17  ±  10  minutes  (Fig.  20A).  However  presentation  of  both  stimuli  (light 
followed  by  novel  wheel  confinement)  resulted  in  an  approximate  77%  attenuation  in  the 
phase  shifting  effect  of  light  (mean  shift  28  ±  13  minutes;  t=6.26,  p<0.01).  Novel  wheel 
exposure  15,30  and  60  minutes  post  photic  stimulation  also  resulted  in  the  attenuation  of 
light  induced  phase  shifts  with  mean  shifts  of  35  ±  14,27  ±  13  and  59  ±  15  minutes 
respectively  (F(7,6o)=12.1,  p<0.05)  (Fig.  20A).  Phase  shifts  observed  from  novel  wheel 
confinement  directly  after  light  stimulation  and  15  to  30  minutes  post  light  pulse  showed 
no  significant  differences  (F(2,24)=  0.1,  p>0.05).  A  90  minute  period  of  DD  between  the 
presentation  of  the  photic  and  non-photic  stimuli  did  not  result  in  a  significant  attenuation 
of  the  phase  shifting  effects  of  light  alone,  with  a  mean  shift  of  83  ±  13  minutes  (t=2.47, 
p>0.05)  (Fig.  21).  Additional  control  group  lb  receiving  novel  wheel  exposure  at  CT18.5, 
CT19,  CT19.5  and  CT20  resulted  in  phase  shifts  of  -1  ±5  minutes,  1±5  minutes,  -4  ±6 
minutes  and  -5  ±5  minutes  respectively  and  were  not  significantly  different  from  novelty 
induced  wheel  running  at  CT18  (F(4,52)=1.1,  p>0.05). 
5.3.2.  Effects  of  NPY  on  light  induced  phase  shifts  at  CT  18 
Vehicle  (ACSF)  administration  directly  after  photic  stimulation  resulted  in  a  phase 
advance  of  105  ±7  minutes,  which  was  not  significantly  different  from  light  stimulation 
alone  (t=1.07,  p>0.05).  Phase  shifts  observed  with  microinjection  of  NPY,  at  CT  18,  were 
120 not  significantly  different  from  shifts  obtained  with  vehicle  administration  alone.  However 
the  administration  of  NPY  directly  after  15  minutes  of  light  exposure  resulted  in  an 
approximate  94%  attenuation  of  the  light  induced  phase  shift  (mean  shift  6±  15  minutes; 
t=6.78,  p<0.05)  (fig.  20B).  NPY  injected  15  and  30  minutes  post  light  stimulation  resulted 
in  the  attenuation  of  the  light  phase  shift  with  mean  shifts  of  3±  15  and  10  ±7  minutes 
respectively  (F(7,  MMý=17.6,  p<0.05).  A  60  minute  delay  between  light  and  NPY 
administration  resulted  in  an  approximate  50%  decrease  in  the  phase  shift  to  light  with  a 
mean  shift  of  61  ±  16  minutes  being  observed  (t=3.65,  p<0.05).  Phase  shifts  resulting  from 
microinjections  of  NPY  directly  after  light  stimulation  and  15  to  30  minutes  post  light 
pulse  showed  no  significant  differences  (F(2,24j=  0.08,  p>0.05)  (Fig.  20B).  However  a  delay 
of  90  minutes  between  photic  stimulation  and  NPY  administration  was  unable  to 
significantly  affect  the  phase  shift  to  light,  resulting  in  a  mean  shift  of  97  ±9  minutes 
(t=1.57,  p>0.05)  (Fig.  21).  Additional  control  group  2b  receiving  icroinjections  of  NPY  at 
CT  18.5,  CT  19,  CT  19.5  and  CT20  resulted  in  phase  shifts  of  -6  ±4  minutes,  -9  ±4 
minutes,  -2  ±4  minutes  and  -5  ±4  minutes  respectively  and  were  not  significantly 
different  from  shifts  observed  at  CT18  following  NPY  administration  (F(4,52)=  0.7,  p>0.05). 
5.3.3.  Functional  cannula  placement  verification 
For  functional  assessment  animals  are  injected  with  a  known  phase  shifting  stimulus.  All 
phase  shifts  seen  in  this  experimental  group  were  comparable  to  those  obtained  in  previous 
studies  (Piggins  et  al.,  1995;  Biello  and  Mrosovsky,  1996;  Mintz  et  al.,  1999;  McArthur  et 
al.,  2000).  The  following  stimuli  were  used  for  functional  assessment:  NPY  injected  at  CT 
6  (200n1  at  a  concentration  of  ing/n1,133  min  ±  9.6  [mean  ±  SEM],  n=10);  GRP  injected 
121 at  CT  14  (150pmol,  200n1,  -191.1min  ±  21.2,  n=4);  NMDA  injected  at  CT  18  (10mM, 
200n1,46  min  ±  10.5,  n=2). 
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LA Figure  20A.  Light  induced  phase  advances  (L)  are  attenuated  by  novel  wheel  exposure 
directly  following  light  stimulation  (LA).  A  delay  of  15,30  and  60  minutes  also  resulted 
in  a  significant  attenuation  of  the  light  induced  phase  advance  at  CT  18,  (LA(15),  LA(30) 
and  LA(60)  respectively;  p<0.05).  Novel  wheel  exposure  90  minutes  post  light  stimulation 
(LA(90))  was  unable  to  significantly  attenuate  the  phase  shift  to  light.  An  activity  pulse 
alone  at  CT  18  (A)  resulted  in  a  minimal  phase  delay,  however  the  ability  of  novel  wheel 
exposure  to  attenuate  light  stimulation  at  CT  18  was  not  merely  an  additive  effect  due  to 
novel  wheel  exposure. 
Figure  20B.  NPY  administration  following  light  stimulation  (LNPY)  resulted  in  an 
attenuation  of  the  phase  advancing  effects  of  light  at  CT  18  (p<0.05).  This  effect  of  NPY 
was  observed  with  administration  15,30  and  60  minutes  post  light  pulse  (LNPY(15), 
LNPY(30)  and  LNPY(60)  respectively).  A  90  minute  delay  between  light  stimulation  and 
NPY  injection  (LNPY(90))  was  unable  to  attenuate  the  phase 
advancing  effects  of  light  at  this  time.  Administration  of  the  vehicle  (V)  at  CT  18  had  little 
effect  on  the  free  running  rhythm.  Vehicle  administration  directly  following  the  photic 
pulse  (LV)  had  no  significant  effect  on  light  induced  phase  shifts  (p>0.05). 
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125 Figure  21.  Representative  actograms  demonstrating  the  attenuation  of  light  induced  phase 
advances  at  CT  18  by  novel  wheel  exposure  and  NPY.  Light  stimulation  alone  resulted  in 
a  phase  advance  at  CT  18  (A).  A  delay  of  up  to  60  minutes  before  exposure  to  a  novel 
wheel  was  able  to  attenuate  the  phase  advancing  effects  of  light  (B),  however  this  was  not 
possible  90  minutes  post  light  exposure  (C).  NPY  administration  directly  after  a  photic 
pulse  resulted  in  a  -94%  attenuation  of  the  phase  advance  due  to  light  (D).  NPY  was  able 
to  attenuate  the  photic  phase  shift  when  administered  up  to  60  minutes  post  light 
stimulation  (E);  this  was  not  possible  90  minutes  after  the  light  pulse  (F).  Times  of  light 
stimulation  are  indicated  by  inverted  open  triangles. 
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Our  results  demonstrate  the  ability  of  non-photic  stimuli  to  attenuate  the  resetting  effects  of 
light  during  the  late  subjective  night  and  thus  confirm  results  from  previous  studies  (Ralph 
and  Mrosovsky,  1992;  Mistlberger  and  Antle,  1998).  Furthermore  the  present  study  was 
designed  to  test  the  limits  of  behavioural  and  neurochemical  stimuli  in  the  attenuation  of 
light  induced  phase  shifts.  Exposure  to  a  novel  running  wheel  and  microinjections  of  NPY 
did  not  have  significant  phase  shifting  effects  late  in  the  subjective  night,  therefore  the 
attenuation  of  light  induced  phase  advancing  were  not  due  to  an  additive  effect.  Novel 
wheel  confinement  and  NPY  administration  directly  following  light  stimulation  and  up  to 
30  minutes  post  light  exposure  showed  no  significant  differences  in  the  extent  to  which 
light  induced  phase  shifts  were  attenuated.  Furthermore  it  would  appear  that  following 
light  exposure,  a  30  minute  window  of  opportunity  exists  in  which  time  novel  wheel 
running  or  NPY  administration  can  maximally  affect  the  resulting  phase  shift  to  light. 
Hence  indicating  that  NPY  release  may  occur  early  in  the  period  of  novel  wheel  exposure. 
Behavioural  activity  is  thought  to  modulate  the  transmission  of  photic  information  within 
the  circadian  system.  Our  results  confirm  previous  work  showing  the  attenuation  of  light 
induced  phase  shifts  by  activity  during  the  late  night,  furthermore  they  shown  that  novel 
wheel  exposure  up  to  60  minutes  after  a  light  pulse  can  also  modulate  the  light  induced 
phase  advance  (Ralph  and  Mrosovsky,  1992;  Mistlberger  and  Antle,  1998).  Such  a  result 
indicates  a  complex  interaction  between  photic  and  non-photic  stimuli.  We  were  unable  to 
significantly  attenuate  the  light  phase  shift  with  novel  wheel  exposure  90  minutes  post 
light  pulse. 
127 Photic  phase  shifts  have  been  shown  to  be  completed  within  1-2  hours  of  light  stimulation 
(Best  et  al.,  1999).  Therefore  our  results  indicate  that  novel  wheel  running  administration 
must  be  within  60  minutes  of  the  light  pulse  if  the  attenuation  is  to  be  observed.  It  would 
appear  that  at  90  minutes  post  light  stimulation  a  majority  of  SCN  cells  have  already  been 
reset  by  light  and  so  novel  wheel  exposure  has  very  little  effect.  It  may  be  that  the  signal 
transduction  cascade  utilised  by  light  has  either  completed  or  is  beyond  the  interaction  site 
of  the  non-photic  stimuli. 
Photic  input  to  the  SCN  is  conveyed  via  a  direct  monosynaptic  projection  from  the  retina 
to  the  SCN,  known  at  the  retinohypothalamic  tract  (RHT).  This  pathway  is  thought  to 
utilise  glutamate  as  its  primary  transmitter  to  relay  photic  information  to  the  SCN.  The 
presence  of  glutamate  in  presynaptic  terminals  of  the  SCN  was  shown  using  ultrastructural 
methods  (Ebling,  1996).  Stimulation  of  the  optic  nerve  in  vitro  releases  glutamate  onto 
SCN  cells  (Liou  et  al.,  1986),  while  optic  nerve  stimulation  in  vivo,  produces  phase  shifts 
that  mimic  those  seen  in  response  to  light  (de  Vries  et  al.,  1994). 
A  second  indirect  pathway  to  the  SCN  arises  from  the  intergeniculate  leaflet  (IGL)  of  the 
lateral  geniculate  nucleus  (LGN)  and  utilises  neuropeptide  Y  as  a  primary  neurotransmitter 
(Harrington,  1997).  The  geniculo-hypothalamic  tract  (GHT)  links  the  IGL  to  the  SCN  and 
is  thought  to  relay  both  photic  and  non-photic  information.  Stimulation  of  the  GHT 
produces  non-photic  like  phase  shifts  (Rusak  et  al.,  1989).  Neuropeptide  Y  administered  in 
vivo  and  in  vitro  also  produces  non-photic  like  phase  shifts  (Albers  and  Ferris,  1984; 
Medanic  and  Gillette,  1993;  Biello  et  al.,  1997b).  Antiserum  to  NPY  can  block  the  phase 
shifts  to  novelty  induced  activity,  indicating  NPY  may  be  important  in  phase  shifts  to 
128 wheel  running  (Biello  et  al.,  1994).  Lesions  of  the  GHT  or  IGL  have  been  shown  to 
interfere  with  phase  shifts  to  non-photic  stimuli  (Biello  et  al.,  1991;  Maywood  et  al.,  1997). 
Non-photic  stimuli  have  also  shown  to  induce  Fos-like  immunoreactivity  in  the  IGL, 
which  is  co-localised  with  NPY  immunoreactivity  (Janik  et  al.,  1995). 
It  is  likely  that  the  IGL  and  its  primary  neurotransmitter,  NPY,  are  involved  in  altering 
phase  shifts  to  light  by  non-photic  behavioural  stimuli,  such  as  novelty  induced  arousal. 
Neuropeptide  Y  containing  fibres,  projecting  from  the  IGL,  have  been  located  in  the 
ventrolateral  portion  of  the  SCN  which  is  also  innervated  by  the  RHT  (Card  and  Moore, 
1989).  NPY  inputs  are  also  likely  to  synapse  on  SCN  cells  receiving  direct  retinal 
information  (Bosler  and  Beaudet,  1985;  van  den  Pol  and  Gores,  1986).  In  addition, 
neurones  activated  by  RHT  stimulation  are  more  likely  to  respond  to  application  of  NPY 
than  those  not  activated  (Shibata  and  Moore,  1988).  Furthermore  this  interaction  shown  by 
in  vitro  experiments  is  supported  by  data  from  in  vivo  work.  Lesions  of  the  GHT  alter  the 
pattern  of  entrainment  (Pickard  et  al.,  1987).  Behavioural  experiments  have  also  shown 
that  administration  of  NPY  can  modulate  the  effects  of  light  pulses  (Weber  and  Rea,  1997). 
In  vitro  experiments  indicate  that  application  of  NPY  can  alter  phase  shifts  to  glutamate  in 
hypothalamic  slice  preparations  of  the  SCN  (Biello  et  al.,  1997a).  Finally  in  vivo-  in  vitro 
model  showed  that  light  pulses  given  in  vivo  were  blocked  by  the  administration  of  NPY  in 
vitro  during  the  early  night  (Yannielli  and  Harrington,  2000). 
The  inhibition  of  photic  phase  shifts  up  to  60  minutes  post  light  stimulation  by  NPY  or 
novel  wheel  exposure  would  suggest  an  intracellular  inhibitory  mechanism  downstream 
from  glutamatergic  receptors.  The  precise  mechanism  by  which  NPY  or  behavioural  non- 
photic  stimuli  inhibit  photic  phase  shifts  is  unclear.  However,  NPY  has  been  shown  to 
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glutamate  (van  den  Pol  et  al.,  1996).  It  is  possible  that  this  neural  depression  may  form 
part  of  the  inhibitory  pathway  induced  by  NPY.  Cells  of  the  SCN  are  depolarised  by 
glutamate  (Meijer  et  al.,  1993)  and  hyperpolarised  by  NPY  (Hall  et  al.,  1999). 
Neuropeptide  Y  activates  a  KK-  selective  conductance  in  the  SCN,  but  KK  channel  blockers 
apparently  attenuated  NPY  phase  shifts  during  the  subjective  day  by  inducing  glutamate 
release  (Hall  et  al.,  1999).  It  is  possible  that  NPY  may  influence  light  induced  phase  shifts 
via  changes  in  K+  conductance.  During  the  subjective  day,  NPY  phase  shifts  are  mediated 
via  the  NPY  Y2  receptor  (Golombek  et  al.,  1996).  However  NPY  blocks  phase  shifts  to 
light  via  the  NPY  Y5  receptor  and  NMDA  induced  phase  shifts  were  inhibited  by  a  NPY 
Y5  agonist,  in  vitro  (Yannielli  and  Harrington,  2001).  NPY  Y5  receptor  activation  has 
been  shown  to  inhibit  the  accumulation  of  the  second  messenger  cyclic  AMP  (Gerald  et  al., 
1996).  Glutamate  induced  phase  shifts  are  blocked  by  the  inhibition  of  protein  kinase  A,  in 
vitro  (Tischkau  et  al.,  2000).  These  findings  suggest  further  possible  sites  for  the 
inhibition  of  photic  phase  shifts  by  NPY. 
Light  or  glutamate  reset  the  circadian  clock  by  utilising  two  different  intracellular 
pathways.  Phase  delays  to  light  in  the  early  night  are  thought  to  be  mediated  via  neuronal 
ryanodine  receptors  (Ding  et  at.,  1998).  However,  phase  advances  late  in  the  night  have 
been  linked  to  a  cyclic  GMP-dependent  pathway  (Weber  et  al.,  1995).  It  would  appear  that 
phase  delays  to  light  and  glutamate  involve  ionotropic  receptors,  whilst  phase  advances 
utilise  mainly metabotrophic  glutamatergic  receptors.  Our  own  in  vivo  work  and  previous 
in  vitro  studies  have  shown  NPY  to  attenuate  both  phase  delays  and  advances  to  light  with 
a  similar  time  course  (Yannielli  and  Harrington,  2000).  Both  phase  delays  and  advances 
130 show  attenuation  by  NPY  administration  up  to  30  minutes  post  light  exposure,  hence 
indicating  that  NPY  is  acting  downstream  from  glutamatergic  receptor  binding  sites. 
Furthermore,  the  interaction  between  NPY  and  light  during  the  early  and  late  night  must  lie 
at  the  level  of  gene  expression,  where  both  the  phase  resetting  pathways  of  light  converge. 
Period  I  (Perl)  and  Period  2  (Per2)  are  two  key  clock  components  localised  to  the  SCN 
(Shearman  et  al.,  1997;  Tei  et  al.,  1997).  Perl  and  Per2  mRNA  levels  (mPerl  and  mPer2, 
respectively)  are  increased  upon  light  stimulation  during  the  subjective  night  (Shearman  et 
al.,  1997;  Zylka  et  al.,  1998).  Antisense  oligodeoxynucleotides  to  the  Perl  sequence  have 
been  shown  to  block  light  or  glutamate  induced  phase  shifts  (Shigeyoshi  et  al.,  1997; 
Akiyama  et  al.,  1999;  Wakamatsu  et  al.,  2001).  Photic  stimulation  results  in  increased 
levels  of  mPerl  and  mPer2  expression  which  peak  after  lhr  and  2hr  respectively  (Albrecht 
et  al.,  1997;  Shigeyoshi  et  al.,  1997;  Zylka  et  al.,  1998).  NPY  reduces  mPerl  and  mPer2 
levels  after  0.5hr  and  2hr  of  NPY  administration  respectively,  furthermore  NPY  YI/Y5 
receptor  agonists  have  also  been  found  to  decrease  Perl  and  Per2  mRNA  levels  with  a  time 
course  similar  to  that  of  NPY  (Fukuhara  et  al.,  2001). 
Both  NPY  and  light  stimulation  influence  mPer2  levels  with  maximum  effects  observed 
2hr  post  stimulation.  However  NPY  reduces  mPerl  within  0.5hr,  while  light  increases 
mPerl  within  Ihr,  indicating  that  NPY  is  faster  than  light  in  inducing  its  effects  on  mPerl. 
In  our  current  study  we  found  that  NPY  was  able  to  attenuate  the  phase  shift  to  light  up  to 
60  minutes  post  light  exposure,  but  was  unable  to  effect  the  photic  phase  shift  when 
administered  90  minutes  post  light  stimulation.  It  would  appear  that  the  rapid  effect  of 
NPY  on  mPerl  levels  allows  NPY  to  reduce  the  increase  in  mPerl  initiated  by  light 
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would  have  peaked  resetting  the  clock,  therefore  NPY  administration  at  this  time  would 
cause  a  maximal  reduction  in  mPerl2hr  post  light  stimulation  and  thus  would  have  no 
effect  on  the  resetting  of  the  clock. 
However  recent  evidence  has  shown  NPY  to  differentially  suppress  mPerl  and  mPer2 
levels  induced  by  light  (Brewer  et  al.,  2002).  Neuropeptide  Y  administration  following 
light,  during  the  early  subjective  night,  resulted  in  mPerl  levels  rapidly  decreasing,  but 
levels  increase  to  match  controls  (light  stimulation  only)  within  60  minutes.  Conversely  a 
sustained  suppression  of  mPer2  was  observed  throughout  the  expected  peak  for  mPer2 
levels  normally  induced  by  light  exposure  alone.  Light  induced  phase  delays  have  been 
found  to  be  strongly  linked  to  the  increase  in  mPer2  levels  and  phase  advances  to  an 
increase  in  mPerl,  in  mice  (Albrecht  et  al.,  2001).  Given  these  current  results  it  is  possible 
that  during  the  late  subjective  night  NPY  rapidly  decreases  mPer2  levels  and  has  a  long- 
term  suppressive  effect  on  mPerl  levels  when  administered  post  light  exposure. 
In  view  of  the  present  investigation  novel  wheel  running  and  NPY  appear  to  be  powerful 
stimuli  in  the  regulation  and  inhibition  of  photic  phase  shifts  during  the  late  subjective 
night.  It  is  clear  that  the  attenuation  of  light  induced  phase  shifts  must  occur  via  a  more 
rapid  signal  transduction  cascade  than  that  utilised  by  light  and  glutamate  at  this  time.  It  is 
evident  that  many  possible  sites  for  the  interaction  of  photic  and  non-photic  stimuli  are 
present  within  SCN  cells.  Therefore  it  will  be  necessary  to  gain  a  further  understanding  of 
the  intracellular  signal  transduction  pathways  utilised  within  this  interaction,  in  order  to 
elucidate  the  underlying  mechanisms  of  such  a  complex  series  of  events. 
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General  Conclusions 
6.1  NPY  and  photic  phase  shifts 
In  the  environment  mammals  display  the  ability  to  adjust  to  naturally  changing 
photoperiods  throughout  the  year.  The  mechanism  used  by  the  circadian  clock  to 
synchronize  to  such  changes  is  not  completely  unclear.  However,  previous  work,  along 
with  my  own  data  strongly  implicates  the  involvement  of  NPY  in  the  modulation  of  photic 
stimuli,  hence  ultimately  in  the  entraining  mechanism  of  the  SCN  in  mammals. 
6.2  Importance  of  the  photic  phase  shift 
Under  constant  conditions  of  darkness  mammals  generally  show  circadian  patterns  of 
either  a  little  over  or  a  little  under  24  hours,  i.  e.  the  tau's  (ti)  of  specific  individuals  can  be 
greater  or  less  than  24.  Thus  in  order  for  such  individuals  to  synchronize  to  a  light-dark 
cycle  of  24  hours  the  circadian  clock  must  be  reset  each  day.  It  must  either  be  pushed 
forward  or  backwards  depending  on  the  individuals  r.  For  mammals  with  ti's  greater  than 
24  hours  the  clock  must  advance  each  day  to  remain  synchronized  with  a  24  hour  light- 
dark  cycle.  Consequently,  mammals  with  T's  less  than  24  hours  must  delay  their  clocks. 
The  mechanism  that  allows  the  entrainment  of  the  circadian  clock  has  been  previously 
studied  and  my  data  now  adds  to  the  evidence  indicating  that  non-photic  stimuli  play  a 
significant  role  in  this  complex  regulation. 
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Neuropeptide  Y  has  been  previously  shown  to  convey  non-photic  information  to  the  SCN. 
Microinjections  of  antiserum,  raised  against  NPY,  directly  onto  the  SCN  blocked  phase 
shifts  to  novel  wheel  exposure,  a  known  non-photic  stimulus  (Biello,  1995).  Furthermore, 
lesions  of  the  IGL  prevented  hamsters  from  phase  shifting  to  the  novel  wheel  (Janik  and 
Mrosovsky,  1994).  Also,  PRC's  from  GHT  stimulation  resembles  those  for  NPY 
microinjections  in  vivo  (Turek  and  Losee-Olson,  1986;  Reebs  and  Mrosovsky,  1989; 
Meyer  et  al.,  1993).  Taken  together,  these  studies  show  the  importance  of  NPY  in  the 
circadian  system  and  its  ability  to  convey  non-photic  information  to  the  SCN. 
Previous  work  and  now  my  own,  show  the  ability  of  NPY  to  interact  with  photic  phase 
shifts  during  the  night.  The  significance  of  such  an  interaction  is  that  it  is  likely  to  be  vital 
for  the  entrainment  of  mammals  to  naturally  changing  environmental  photoperiods.  Thus 
NPY  provides  one  possible  mechanism  for  the  modulation  of  photic  phase  shifts,  enabling 
mammals  to  obtain  precise  synchronization  with  the  environment. 
6.4  Interaction  between  NPY  and  light 
Interactions  between  NPY  and  light  have  been  previously  shown.  Phase  advances  to  light 
were  blocked  by  NPY  microinjection,  in  vivo  (Weber  and  Rea,  1997).  Furthermore,  both 
phase  delays  and  advances  to  light  were  blocked  by  NPY  administration  in  vitro 
(Harrington,  1997).  My  work  using  a  slightly  different  in  vivo  paradigm,  mainly  involving 
the  microinjection  of  NPY  following  light  exposure,  has  shown  that  NPY  inhibits  phase 
advances  to  light  and  also  attenuates  phase  delays.  Taken  together  these  studies  indicate  a 
role  for  NPY  in  the  inhibition  of  photic  phase  shifts.  The  fact  that  NPY  inhibits  phase 
134 advances  and  attenuates  phase  delays  may  be  of  importance  and  may  suggest  differences  in 
the  regulatory  mechanisms  in  place  for  the  maintenance  of  light  induced  phase  shifts. 
6.5  Mechanisms  for  the  interaction  between  NPY  and  light 
Phase  shifts  to  NPY  were  found  to  utilize  the  Y2  receptor  subtype  (Huhman  et  al.,  1996; 
Biello  et  al.,  1997b).  However,  in  vitro  data  had  indicated  that  the  Y2  receptor  was  not 
involved  in  the  inhibitory  actions  of  NPY  on  photic  phase  shifts.  In  my  first  series  of 
experiments,  I  found  that  a  specific  Y1/Y5  receptor  agonist  was  able  to  influence  photic 
phase  shifts  in  a  similar  manner  to  NPY.  With  the  next  set  of  experiments,  I  found  that  by 
preventing  NPY  from  binding  to  the  Y5  receptor  using  a  novel  Y5  antagonist  I  was  able  to 
block  the  inhibitory  effects  of  NPY  on  light  induced  resetting  of  the  clock.  The  Y1 
receptor  antagonist  had  no  effect  on  the  interaction  between  NPY  and  light  during  the 
night.  Thus  it  would  appear  that  NPY  initiates  its  inhibitory  effects  on  photic  phase  shifts 
via  the  activation  of  the  Y5  receptor  subtype. 
Having  established  the  receptor  subtype  utilized  by  NPY  in  its  complex  interaction  with 
light  the  next  step  was  to  identify  a  possible  neural  or  intracellular  pathway  by  which  NPY 
mediates  its  influence  on  photic  phase  shifts.  It  has  been  previously  shown  that  during  the 
day  NPY  resets  the  circadian  clock  via  a  pathway  involving  GABAergic  interneurons.  In 
this  study  bicuculline,  a  GABAA  antagonist  blocked  the  phase  resetting  effects  of  NPY,  in 
vivo.  My  next  stage  of  investigation  was  to  see  if  NPY  utilized  this  same  GABA 
dependent  mechanism  in  the  inhibition  of  light  induced  phase  shifts.  I  found  that 
bicuculline  did  not  prevent  NPY  from  blocking  photic  phase  advances  and  attenuating 
135 phase  delays.  Further,  I  also  found  that  bicuculline  potentiated  light  induced  phase  delays, 
but  had  no  effect  on  phase  advances. 
The  increases  in  the  phase  delays  to  light  observed  with  bicuculline  are  possibly  due  to  the 
disruption  of  a  natural  GABAergic  tone  present  on  SCN  cells  at  this  time.  Muscimol,  a 
GABAA  agonist,  is  able  to  block  the  phase  delays  to  light.  Hence  if  a  continuous  tone  were 
present,  SCN  cells  would  be  under  the  influence  of  GABA  during  the  early  night,  therefore 
photic  phase  shifts  would  be  naturally  reduced  i.  e.  the  magnitude  we  see  in  a  normal  photic 
PRC.  Thus,  the  addition  of  a  GABA  antagonist  would  ultimately  reduce  the  GABAergic 
tone  on  the  SCN  and  prevent  the  inhibitory  actions  of  GABA  on  light  induced  phase  shifts. 
During  the  late  night  it  is  possible  that  GABAergic  tone  is  reduced  therefore  administration 
of  bicuculline  has  no  effect  on  photic  phase  shifts. 
Interestingly,  microinjections  of  the  Y5  antagonist  resulted  in  the  potentiation  of  the  phase 
advances  to  light,  but  had  no  effect  on  phase  delays.  Taken  together,  it  is  possible  that 
during  the  early  night  a  GABA  dependent  mechanism  is  active  in  the  regulation  of  the 
photic  phase  shift.  However,  during  the  late  night  NPY  may  modulate  phase  advances  to 
light. 
This  interpretation  of  the  experimental  results  displays  the  plasticity  of  the  circadian 
system  and  the  diversity  of  the  modulatory  mechanisms  present  for  the  regulation  and 
preservation  of  the  photic  phase  shift  and  ultimately  entrainment. 
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level 
General  conclusions  from  my  data  would  suggest  that  the  interaction  between  NPY  and 
light  occurs  at  the  level  of  the  SCN.  It  is  likely  that  NPY  opposes  the  cellular  effects  of 
light  in  order  to  prevent  photic  phase  shifts.  One  way  of  doing  this  would  be  to  interfere 
with  the  intracellular  pathway  induced  by  light  via  glutamate  release  from  the  RHT 
(Ebling,  1996).  Throughout  the  night  phase  shifts  to  light  require  the  activation  of  multiple 
glutamatergic  receptor  subtypes,  of  which  NMDA  receptors  are  critical  (Colwell  and 
Menaker,  1992;  Ding  et  al.,  1994;  Shibata  et  al.,  1994;  Mintz  et  al.,  1999).  Activation  of 
such  receptors  results  in  the  influx  of  Ca2+  ions,  which  in  turn  activate  nitric  oxide  synthase 
(NOS)  to  produce  nitric  oxide  (NO)  (Ding  et  al.,  1994;  Amir  et  al.,  1995).  At  this  point  the 
photic  pathway  diverges.  In  the  early  night,  light/glutamate  requires  the  release  of 
intracellular  Ca2+  ions  via  the  activation  of  neuronal  ryanodine  receptors  (RYR)  in  order  to 
phase  shift.  However,  during  the  late  night  photic  stimuli  utilize  a  cGMP/protein  kinase  G 
(PKG)  dependent  signal  transduction  cascade  (Weber  et  al.,  1995;  Mathur  et  al.,  1996; 
Ding  et  al.,  1998).  Finally,  light  /glutamate  signals  during  the  early  and  late  night  induce 
the  phosphorylation  of  Ca2+/cAMP  response  element  binding  protein  (CREB)  which  leads 
to  CRE-mediated  transcription  activation  (Ginty  et  al.,  1993;  Ding  et  al.,  1997;  Obrietan  et 
al.,  1999). 
The  intracellular  pathway  utilized  by  NPY  is  unclear.  Currently,  studies  have  been  aimed 
at  investigating  the  signaling  molecules  activated  by  NPY  during  the  day,  i.  e.  at  times 
when  NPY  induces  phase  shifts.  It  is  possible  that  NPY  utilizes  the  same  or  a  similar 
mechanism  in  its  ability  to  interact  with  photic  stimuli.  In  the  first  instance,  NPY  produces 
137 long-term  depression  in  intracellular  calcium  levels  within  SCN  cells  stimulated  with 
glutamate  (van  den  Pol  et  al.,  1996).  This  would  suggest  that  NPY  might  interact  with 
photic  phase  shifts  upstream  from  NOS  activation.  However,  this  is  unlikely  due  to  the 
differences  observed  with  NPY  and  during  the  early  and  late  night.  Therefore  the  site  of 
interaction  is  most  probably  post  NO  synthesis.  The  inhibition  of  protein  kinase  C  (PKC) 
blocks  NPY  phase  advances  (Biello  et  al.,  1997b).  Also  NPY  increases  selective  K+ 
conductance  across  SCN  cell  membranes  (Hall  et  al.,  1999),  however  this  is  not  required 
for  NPY  phase  shifts,  and  may  be  possibly  linked  to  NPY's  interaction  with  light. 
Furthermore,  protein  synthesis  inhibitors  did  not  prevent  NPY  induced  phase  shifts  (Hall  et 
al.,  1999),  suggesting  that  NPY  may  be  acting  to  reduce  protein  synthesis  within  the  SCN. 
The  divergence  in  the  photic  pathway  may  account  for  the  difference  observed  with  NPY's 
ability  to  attenuate  phase  delays  and  inhibit  advances  to  light.  The  signal  transduction 
cascade  for  delays  to  light  are  likely  to  be  completed  faster  than  those  for  advances  due  to 
the  activation  of  RyR's  and  the  rapid  influx  of  Ca2+  ions  from  intracellular  stores  (Ding  et 
al.,  1998).  Therefore,  the  key  site  for  the  interaction  between  NPY  and  light  may  lie  at  the 
rate  of  CRE-mediated  transcriptional  activation.  With  activation  being  faster  with  phase 
delays.  This  would  suggest  that  the  site  of  interaction  lies  at  the  level  of  gene  transcription. 
From  this  evidence  it  is  possible  to  speculate  a  physiological  pathway  utilized  by  NPY  in 
its  interaction  with  photic  phase  shifts.  Initially,  during  the  night  NPY  binds  to  the  Y5 
receptor  (Lall  and  Biello,  Submitted),  this  then  may  activate  a  PKC  dependent  pathway 
and/or  a  cAMP/PKA  mechanism.  Both  PKC  and  cAMP  agonists  show  phase  shifts  similar 
to  those  observed  with  NPY  (Biello  et  al.,  1997b).  Furthermore,  PKC  inhibitors  block 
138 NPY  phase  shifts.  Ultimately  this  pathway  will  prevent  the  production  of  clock  related 
genes  normally  increased  by  light  stimulation. 
Other  neurotransmitters  involved  in  non-photic  phase  shifts  may  also  play  a  role  in  the 
mechanism  of  interaction  between  NPY  and  light.  GABA  agonists  inhibit  both  phase 
delays  and  advances  to  light  (Gillespie  et  al.,  1996;  Gillespie  et  al.,  1997).  Further,  both 
NPY  and  GABA  are  co-localized  within  the  same  synaptic  terminals  (Francoisbellan  et  al., 
1990).  My  data  shows  that  the  GABAA  dependent  pathway  is  not  a  mechanism  used  by 
NPY  in  its  inhibitory  effects  of  light.  However,  it  is  possible  that  NPY  utilizes  a  GABAB 
and/or  GABAC  dependent  pathway  in  this  interaction.  Serotonergic  fibres,  from  the  raphe 
nuclei,  synapse  onto  SCN  cells  that  also  receive  NPY  and  glutamatergic  innervation 
(Morin  et  al.,  1992).  Activity  induced  phase  shifts,  mediated  via  NPY  release,  are 
unaffected  by  depletion  of  serotonin  input  to  the  SCN  (Bobrzynska  et  al.,  1996).  However, 
the  behavioural  inhibition  of  light  induced  phase  advances  was  prevented  by  the 
administration  of  a  serotonergic  antagonist  (Mistlberger  and  Antle,  1998).  This  would 
suggest  that  serotonin  and  GABA  also  play  a  role  in  the  inhibition  of  photic  phase  shifts. 
Overall,  it  is  likely  that  the  majority  of  neurotransmitters  mediating  non-photic  stimuli 
have  the  ability  to  interact  with  photic  stimuli.  The  integration  of  all  these  various 
subsystems  probably  allows  the  plasticity  and  precision  required  for  the  functioning  and 
ultimately  the  entrainment  of  the  circadian  clock. 
139 6.7  NPY  and  light  at  the  molecular  level 
Previous  studies  have  shown  NPY  to  oppose  the  actions  of  light  at  the  molecular  level. 
Together  with  my  own  data  (chapter  5)  it  is  likely  that  the  interaction  between  NPY  and 
light  occurs  at  the  level  of  gene  transcription  and/or  protein  synthesis. 
Light  stimulation  results  in  the  increase  of  the  circadian  gene  period  (Per)  mRNA  (mPer) 
levels  (Shearman  et  al.,  1997;  Zylka  et  al.,  1998).  Neuropeptide  Y  administration  has  been 
shown  to  reduce  mPer  levels  in  hamsters  and  mice  (Fukuhara  et  al.,  2001;  Maywood  et  al., 
2002). 
Cytosolic  PER  protein  concentrations  are  regulated  via  three  major  cellular  mechanisms. 
A  dimer  formed  from  the  Clock  and  Bmall  proteins  (CLK  and  BMAL1,  respectively) 
initiate  mPer  synthesis.  The  CLK/BMAL1  dimer  binds  to  the  promotor  site  of  the 
numerous  homologs  of  the  period  gene  and  starts  the  expression  of  mPer.  The  second 
mechanism  involves  an  enzyme  called  casein  kinase  le  (cklc),  which  acts  to  phosphorylate 
PER.  The  phosphorylated  PER  (pPER)  forms  homodimers  with  other  pPER  proteins, 
which  prevents  mPer  expression.  Finally  the  synthesis  of  cryptochrome  proteins  (CRY) 
also  aid  the  regulation  of  mPer  synthesis  by  forming  heterodimers  with  pPER  and  down 
regulating  mPer  transcription  (see  (van  Esseveldt  et  al.,  2000)  for  review  of  molecular 
genetics  of  the  SCN). 
This  molecular  mechanism  presents  various  sites  for  NPY  to  inhibit  the  synthesis  of  mPer 
initiated  by  photic  stimulation.  It  is  possible  that  NPY  is  able  to  prevent  the  binding  of  the 
CLK/BMAL1  dimer  to  the  promoter  sites  of  the  period  genes.  Neuropeptide  Y  may  also 
140 act  to  degrade  the  CLK/BMAL1  dimer  during  the  night.  An  increase  in  the  cytosolic 
concentration  of  cklc  by  NPY  stimulation  would  result  in  the  rise  of  pPER,  ultimately 
leading  to  the  increase  of  PER/PER  homodimers,  again,  preventing  mPer  synthesis.  Also 
the  increase  in  the  rate  of  synthesis  of  CRY  would  promote  the  formation  of  PER/CRY 
heterodimers,  thereby  inhibiting  mPer  synthesis.  These  speculations  also  fit  into  various 
molecular  models  proposed  for  the  regulation  of  entrainment  in  mammals  (Shearman  et  al., 
2000). 
Photic  phase  shifts  have  been  linked  to  the  expression  of  differing  homologs  of  PER. 
Light  induced  phase  delays  have  been  strongly  linked  to  increases  in  mPer2,  while  phase 
advances  to  increases  in  mPerl  (Albrecht  et  at.,  2001).  Recently,  during  the  early  night 
NPY  was  shown  to  differentially  suppress  mPerl  and  mPer2  levels  following  light 
stimulation,  such  that  there  was  a  sustained  suppression  of  mPer2  (Brewer  et  al.,  2002). 
However,  during  the  late  night  novelty  induced  wheel  running,  mediated  via  NPY  release, 
did  not  inhibit  photic  phase  shifts  via  a  mechanism  involving  the  down  regulation  of 
mPerl  (Edelstein  et  al.,  2003).  Taken  together  this  may  indicate  that  either  NPY  interacts 
with  photic  phase  shifts  via  the  long-term  suppression  of  mPer2  or  that,  during  the  late 
night  NPY  inhibits  photic  resetting  via  a  mechanism  independent  of  PER  regulation. 
It  is  clear  that  from  these  speculations  more  work  is  required  in  the  understanding  of  the 
molecular  actions  of  NPY  on  the  circadian  clock. 
141 6.8  The  Future 
It  is  evident  that  from  the  experiments  included  in  this  thesis  that  NPY  input  from  the  IGL 
is  important  in  the  regulation  of  photic  phase  shifts  and  ultimately  in  the  entrainment  of  the 
mammalian  circadian  clock. 
Further  studies  are  required  in  order  to  fully  understand  the  mechanism  underlying  the 
interaction  between  NPY  and  light  during  the  night.  My  studies  have  shown  that  NPY 
utilizes  the  Y5  receptor  subtype,  at  the  level  of  the  SCN,  in  its  inhibition  of  the  resetting 
effects  of  light. 
Future  work  should  be  focused  on  determining  the  intracellular  signaling  cascade 
associated  with  the  Y5  receptor  and  ultimately  the  molecular  influences  bought  about  by 
its  activation.  Further  investigations  into  the  differences  between  NPY's  ability  to  interact 
with  photic  phase  delays  and  advances  also  need  to  be  addressed.  It  is  unclear  if  the  reason 
for  such  a  difference  is  due  to  the  photic  intracellular  pathway  or  the  mechanism  used  by 
NPY  to  influence  light  induced  phase  shifts  at  varying  times  throughout  the  night.  Also 
the  role  of  other  non-photic  mediators  need  to  be  investigated,  and  their  part  in  this 
complex  interaction  between  NPY  and  light.  The  long-term  aim  of  such  research  is  to 
establish  the  precise  mechanism  by  which  the  circadian  system  fine-tunes  entrainment  to 
the  natural  environment. 
Both  photic  and  non-photic  stimuli  are  essential  for  the  regulation  and  entrainment  of  the 
circadian  clock  to  our  natural  environment.  Understanding  the  underlying  mechanisms  by 
which  such  stimuli  interact  will  provide  invaluable  information  regarding  circadian  clock 
142 function.  Ultimately  such  information  would  be  beneficial  in  the  treatment  of  many 
circadian  related  conditions  and  disorders,  such  as  jet  lag  and  depression. 
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Cannulation  surgical  procedure 
Apparatus  Preparation:  all  surgical  instruments  were  autoclaved  before  use.  The  stero- 
taxic  frame  and  accessories  were  all  swabbed  down  with  70%  alcohol  as  well  as 
surrounding  surgical  surfaces. 
Anesthetic  setup:  halothane  was  used  throughout  this  procedure.  Animals  were 
anaesthetized  in  an  enclosed  chamber  with  inlet  valves  for  oxygen  and  anesthetic.  Oxygen 
flow  into  the  chamber  was  set  to  1  liter  per  minute.  Halothane  levels  were  set  to  6%  whilst 
the  animal  was  confined  to  the  chamber.  Once  the  animal  had  been  placed  into  the  stero- 
taxic  and  the  anesthetic  mask  fitted,  halothane  levels  were  reduced  to  3%,  but  oxygen 
levels  remain  unaltered. 
Animal  preparation:  male  Syrian  hamsters  weighing  approximately  90  -100  grams  were 
used  for  this  procedure.  Initially  animals  were  weighed  and  placed  into  the  anesthetic 
chamber.  Once  the  animal  became  ataxic  it  was  taken  out  of  the  chamber  and  the  head 
shaved  using  an  electric  shaver  and  then  placed  back  into  the  chamber.  At  this  stage  the 
animal  was  left  in  the  chamber  until  it  was  completely  under  the  influence  of  the 
anesthetic.  A  typical  test  for  this  was  the  absence  of  a  toe  pinch  reflex. 
Stero-taxic  preparation:  one  of  the  ear  bars  was  set  to  0.5  and  locked  into  position.  The 
platform  on  which  the  animals  was  to  lie  was  set  so  that  once  the  animal  was  in  the  stero- 
taxic  its  head  was  level  with  the  plane  of  the  ear  bars.  The  guide  cannula  was  placed  into 
cannula  holder  and  secured. 
144 Placing  the  animal  into  the  stero-taxic:  once  the  animal  was  under  the  anesthetic  in  the 
chamber  it  was  placed  onto  the  stero-taxic  platform  with  its  nose  firmly  in  the  anesthetic 
mask  and  ears  level  with  the  ear  bars.  One  ear  was  placed  over  the  secure  ear  bar.  This 
was  used  to  anchor  the  animal's  head.  Once  the  head  felt  as  though  it  was  anchored  via  a 
bone  ridge  on  the  skull  the  head  was  held  flat  and  the  second  ear  bar  placed  into  the  other 
ear.  Finally  the  incisors  were  secured  in  the  incisor  bar  and  pulled  tort. 
Cannulation:  using  a  number  l0A  scalpel  blade  an  incision  of  approximately  1.5  cm  was 
made  along  the  skull  to  reveal  the  skull  surface.  Then  surrounding  muscle  was  scraped 
back  to  uncover  the  skull  markings.  Using  a  cotton  swab  a  little  ethanol  was  applied  to  the 
skull  surface  whilst  drying  the  skull  using  a  blow  dryer.  Once  bregma  was  visually 
predominant  the  guide  cannula  was  lined  up  at  the  point  at  which  the  midline  and  bregma 
met.  The  co-ordinates  were  noted  for  the  vertical,  horizontal  and  longitudinal  axis.  These 
were  then  adjusted  according  to  the  sterio-taxic  co-ordinates  for  aiming  the  guide  cannula 
to  the  third  ventricle  or  suprachiasmatic  nucleus  (see  individual  chapter  sections  on 
experimental  procedures).  The  new  position  of  the  guide  cannula  was  marked  and  a  hole 
of  approximately  0.1  cm  was  drilled  using  an  electronic  hand  drill.  Three  screws 
(approximately  0.2  cm  in  length)  were  fixed  around  the  drilled  hole  in  a  triangular 
formation.  The  guide  cannula  was  then  lowered  to  the  desired  depth.  Small  pieces  of  gel 
foam  were  placed  between  the  skull  surface  and  the  base  of  the  guide  cannula  pedestal. 
Dental  cement  was  applied  around  the  guide  cannula  and  the  screws  to  form  a  smooth 
dome.  Once  dry  the  skin  was  sutured  together  using  surgical  glue.  The  animal  was  taken 
145 out  of  the  ear  bars,  anesthetic  mask  and  incisor  bar  and  placed  into  a  warm  box  until  the 
animal  recovered  from  the  anesthetic. 
After  care:  post  surgery  animals  were  injected  with  0.5  mis  of  saline  and  buprenorphine 
(0.5mg/Kg).  Animals  were  also  given  mashed  diet,  which  consisted  of  food  being  crushed 
and  turned  into  a  pulp  by  adding  water.  The  animal's  body  weight  was  also  monitored 
over  a  seven-day  period  following  surgery. 
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Dose  response  analysis  of  RWJ57926  in  the  inhibition  of  photic  phase  shifts  by  NPY 
Introduction 
Previous  work  has  shown  NPY  to  inhibit  photic  and  phase  advances  and  attenuate  phase 
delays.  Furthermore,  this  interaction  was  shown  to  involve  the  activation  or  either  the  Y1 
or  Y5  receptor  (Lall  and  Biello,  2003b).  A  recent  in  vitro  study  found  that  a  Y5  receptor 
antagonist  inhibited  the  attenuating  effects  of  NPY  on  NMDA  induced  phase  shifts 
(Yannielli  and  Harrington,  2001). 
This  study  was  designed  to  establish  a  dose  response  relationship  between  a  novel  NPY  Y5 
antagonist  and  its  effects  on  the  interaction  between  NPY  and  light. 
147 Materials  and  methods 
Subjects 
Experimental  procedures  were  carried  out  under  licence  by  the  Home  Office  (UK)  in 
accordance  with  the  Animals  (Scientific  Procedures)  Act  (1986).  Adult  male  Syrian 
hamsters  (40  days  old,  Harlan  Sprague-Dawley,  Oxon,  UK)  were  housed  individually  in 
plastic  cages  fitted  with  16  cm  running  wheels  connected  to  a  computer  that  summed 
wheel  revolutions  in  10  minute  activity  bins  (Dataquest  Pro-Data  software,  Data  Sciences 
Inc.,  Roseville,  MN,  USA).  Food  and  water  were  available  ad  libitum.  Animals  (n=12) 
were  maintained  under  a  LD  cycle  of  14  hours  light  and  10  hours  of  darkness  and  then 
transferred  to  constant  conditions  (22  ±  2°C;  14-18  lux  dim  red  light)  10  days  before 
treatment.  Animals  were  re-entrained  by  this  method  following  a  maximum  of  three 
treatments  before  continuing  with  further  experimental  conditions.  All  efforts  were  made 
to  minimise  the  number  of  animals  used  and  their  suffering. 
Surgery  and  Injections 
See  appendix  I  for  a  detailed  description  of  the  surgical  procedure. 
Hamsters  were  anaesthetised  with  halothane  gas  throughout  the  length  of  the  surgery. 
Animals  received  cannula  guides,  which  were  implanted  to  a  depth  of  5.6mm  below  the 
skull  surface  at  a  10°  angle  and  fixed  to  the  skull  with  fine  machine  screws  and  dental 
cement.  Cannula  guides  were  stereotaxically  aimed  at  the  SCN  (co-ordinates  relative  to 
bregma:  AP+0.4mm,  ML  1.0mm,  upper  incisor  bar  -2  mm).  After  recovery  from  surgery 
(1  week  under  LD  14:  1Oh),  animals  were  transferred  into  cages  fitted  with  running  wheels 
and  maintained  for  7-10  days  under  LD  14:  1Oh  before  being  placed  into  constant 
conditions.  In  all  treatments  the  vehicle  consisted  of  a  0.9%  saline  solution.  Porcine  NPY 
148 (234µM  in  200nl  saline,  Calbiochem,  UK),  Y5  antagonist  RWJ57926  ([a-(3- 
pyridylmethyl)-ß-aminotetralin-derived  sulfonamide];  4µM,  2µM,  1µM,  0.5µM  in  200n1 
saline;  RW  Johnson  Pharmaceutical  Research  Institute),  were  administered  using  a  28 
gauge  infusion  cannula  attached  to  a1  µl  Hamilton  syringe.  The  infusion  cannula  extended 
2.4  mm  from  the  base  of  the  guide  cannula. 
Experimental  treatments 
Prior  to  the  start  of  the  experiment  all  animals  were  injected  with  NPY  at  CT  6  five  days 
after  being  placed  into  constant  conditions.  These  microinjections  were  used  as  functional 
assessments  to  verify  cannula  placements. 
Animals  were  randomly  divided  into  four  groups  each  consisting  of  three  hamsters.  Group 
1  received  a  15-minute  light  pulse  at  CT18  with  Y5  antagonist  (4µM)  administration  at 
CT18.08  and  NPY  administration  at  CT18.17.  Group  2  received  a  15-minute  light  pulse  at 
CT18  with  Y5  antagonist  (2µM)  administration  at  CT18.08  and  NPY  administration  at 
CT18.17.  Group  3  received  a  15-minute  light  pulse  at  CT18  with  Y5  antagonist  (1µM) 
administration  at  CT18.08  and  NPY  administration  at  CT18.17.  Group  4  received  a  15- 
minute  light  pulse  at  CT18  with  Y5  antagonist  (0.5µM)  administration  at  CT18.08  and 
NPY  administration  at  CT18.17. 
Data  analysis 
For  activity  onset  calculation  see  appendix  III. 
Data  from  each  set  of  treatments  was  analysed  by  the  one-way  repeated  measures 
ANOVA,  followed  by  Bonferroni  method  for  multiple  comparisons. 
149 Cannula  Placement 
See  appendix  IV  for  cannula  placement  assessment  methods. 
150 Results 
Table  I  shows  the  phase  shifts  observed  during  the  late  night  with  varying  concentrations 
of  RWJ57926  during  light  stimulation  followed  by  NPY  microinjection  (F(g,  11ý=  198). 
Figure  22  illustrates  the  dose  relationship  of  the  Y5  antagonist  with  light  and  NPY 
treatments. 
Table  1 
[RWJ57926]  µM  Phase  shift  (mean  minutes  ±  SEM;  n=3  in  all 
groups) 
4*  486±20 
2  164±9 
1  162±6 
0.5  171±4 
Table  1.  Phase  shifts  obtained  from  microinjects  of  the  Y5  antagonist  during  light  exposure  followed  by 
NPY  administration  (*  indicatesp<0.001). 
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Figure  22  illustrates  the  dose  response  relationship  observed  with  the  Y5  antagonist,  light  and  NPY. 
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Figure  23.  Representative  actograms  illustrating  the  phase  shifts  obtained  with  the  microinjection  of  varying 
concentrations  of  RWJ57926  with  light  and  NPY. 
153 Conclusion 
The  ability  of  NPY  to  block  photic  phase  shifts  was  prevented  by  the  presence  of  the  NPY 
Y5  receptor  antagonist.  The  higher  dose  of  the  antagonist  resulted  in  the  significant 
potentiation  of  the  photic  phase  shift.  Lower  doses  of  the  drug  showed  no  variation  in  the 
phase  shift  to  light.  A  recent  in  vitro  study  shows  that  a  2µM  dose  of  RWJ57926  was 
effective  in  inhibiting  the  ability  of  NPY  to  block  NMDA  induced  phase  shifts  (Yannielli 
and  Harrington,  2001).  From  this  set  of  experiments  and  those  preformed  in  vitro,  it  was 
concluded  that  a  2µM  concentration  of  RWJ57926  be  used  for  the  series  of  experiments 
preformed  in  chapter  3. 
154 Appendix  III 
Onset  calculation 
Activity  onset  times  (CT12)  for  the  day  of  treatment  were  calculated  by  forward 
extrapolation  of  a  regression  line  fitted  to  seven  onsets  pre-treatment.  Activity  onsets  were 
defined  as  the  first  10  minute  bin  with  at  least  50  wheel  revolutions,  following  a  period  of 
no  activity  for  at  least  6  hours,  followed  by  a  second  10  minute  bin  with  50  or  more  wheel 
revolutions  within  30  minutes.  Post-treatment  activity  onsets  for  the  day  of  treatment  were 
calculated  by  back  extrapolation  of  a  regression  line  fitted  to  seven  activity  onsets  post- 
treatment.  The  initial  3  days  post-treatment  were  excluded  from  the  regression 
calculations  to  allow  for  any  transient  effects.  Phase  shifts  were  calculated  as  the 
difference  between  pre-treatment  and  post-treatment  activity  onsets. 
155 Appendix  IV 
Cannula  placement  analysis  methods 
Cannula  placements  were  identified  by  histological  and/or  functional  assessment. 
Histology:  animals  were  killed  using  an  overdose  of  sodium  pentobarbital  (about  160 
mg/kg,  i.  p.  )  and  given  an  intracerebral  injection  of  Indian  ink  (400n1)  with  the  same  length 
of  injector  used  in  the  experiment.  They  were  then  perfused  transcardially  with  0.9% 
saline  and  10%  formaldehyde.  The  brains  were  postliixed  in  10%  formalin  with  30% 
sucrose.  Frontal  sections  (40  µm)  were  cut  using  a  cryostat.  Slices  containing  the  SCN 
were  mounted  on  Polysine  microslides  and  stained  for  Nissl  substance  with  Cresyl  Violet. 
The  distance  from  the  injection  site  to  the  margin  of  the  SCN  was  measured  along  the 
anterior-posterior,  dorsal-ventral  and  lateral  axes.  The  greatest  of  the  three  measurements 
was  taken  as  the  distance  from  the  SCN.  No  data  from  animals  with  placements  more  than 
400µm  from  the  margin  of  the  SCN  was  included  in  subsequent  analyses. 
156 Appendix  V 
Cannula  placement  site 
Figure  24. 
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Figure  24.  A  representative  coronal  photomicrograph  of  a  hamster  brain  detailing  the  verification  of  the 
cannula  microinjection  site. 
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